
Call for Editorial Board Members

As you are well aware that we are a medical and health sciences publishers; publishing peer-reviewed journals and books since 2004.

We are always looking for dedicated editorial board members for our journals. If you completed your master's degree and must have at least five years experience in teaching and having good publication records in journals and books.

If you are interested to be an editorial board member of the journal; please provide your complete resume and affiliation through e-mail (i.e. info@rfppl.co.in) or visit our website (i.e. www.rfppl.co.in) to register yourself online.

Call for Publication of Conference Papers/Abstracts

We publish pre-conference or post-conference papers and abstracts in our journals, and deliver hard copy and giving online access in a timely fashion to the authors.

For more information, please contact:

For more information, please contact:
A Lal
Publication-in-charge
Red Flower Publication Pvt. Ltd.
48/41-42, DSIDC, Pocket-II
Mayur Vihar Phase-I
Delhi - 110 091 (India)
Phone: 91-011-79695648
E-mail: info@rfppl.co.in

Free Announcements of your Conferences/Workshops/CMEs

This privilege to all Indian and other countries conferences organizing committee members to publish free announcements of your conferences/ workshops. If you are interested, please send your matter in word formats and images or pictures in JPG/JPEG/Tiff formats through e-mail attachments to sales@rfppl.co.in.

Terms & Conditions to publish free announcements:

1. Only conference organizers are eligible up to one full black and white page, but not applicable for the front, inside front, inside back and back cover, however, these pages are paid.
2. Only five pages in every issue are available for free announcements for different conferences.
3. This announcement will come in the next coming issue and no priority will be given.
4. All legal disputes subject to Delhi jurisdiction only.
5. The executive committee of the Red Flower Publication reserve the right to cancel, revise or modify terms and conditions any time without prior notice.

For more information, please contact:

A Lal

Publication-in-charge

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091 (India)

Phone: 91-011-79695648

E-mail: info@rfppl.co.in

Win Free Institutional Subscription!

Simply fill out this form and return scanned copy through e-mail or by post to us.

Name of the Institution_____

Name of the Principal/Chairman_____

Management (Trust/Society/Govt./Company)_____

Address 1_____

Address 2_____

Address 3_____

City_____

Country_____

PIN Code_____

Mobile_____

Email_____

We are regular subscriber of Red Flower Publication journals.

Year of first subscription_____

List of ordered journals (if you subscriberd more than 5 titles, please attach separate sheet)

Ordered through

Name of the Vendor	Subscription Year	Direct/subs Yr

Name of the journal for which you wish to be free winner

Terms & Conditions to win free institutional subscription

1. Only institutions can participate in this scheme
2. In group institutions only one institution would be winner
3. Only five institutions will be winner for each journal
4. An institution will be winner only for one journal
5. The free subscription will be valid for one year only (i.e. 1 Jan - 31 Dec)
6. This free subscription is not renewable, however, can be renewed with payment
7. Any institution can again participate after five years
8. All legal disputes subject to Delhi jurisdiction only
9. This scheme will be available to participate throughout year, but draw will be held in last week of August every year
10. The executive committee of the Red Flower Publication reserve the right to cancel, revise or modify terms and conditions any time without prior notice.

I confirm and certify that the above information is true and correct to the best of my knowledge and belief.

Place:

Signature with Seal

Date:

Revised Rates for 2023 (Institutional)		Frequency	India(INR) Print Only	India(INR) Online Only	Outside India(USD) Print Only	Outside India(USD) Online Only
Title of the Journal						
Community and Public Health Nursing		Triannual	6500	6000	507.81	468.75
Indian Journal of Agriculture Business		Semiannual	6500	6000	507.81	468.75
Indian Journal of Anatomy		Quarterly	9500	9000	742.19	703.13
Indian Journal of Ancient Medicine and Yoga		Quarterly	9000	8500	703.13	664.06
Indian Journal of Anesthesia and Analgesia		Bi-monthly	8500	8000	664.06	625
Indian Journal of Biology		Semiannual	6500	6000	507.81	468.75
Indian Journal of Cancer Education and Research		Semiannual	10000	9500	781.25	742.19
Indian Journal of Communicable Diseases		Semiannual	9500	9000	742.19	703.13
Indian Journal of Dental Education		Quarterly	6500	6000	507.81	468.75
Indian Journal of Diabetes and Endocrinology		Semiannual	9000	8500	703.13	664.06
Indian Journal of Emergency Medicine		Quarterly	13500	13000	1054.69	1015.63
Indian Journal of Forensic Medicine and Pathology		Quarterly	17000	16500	1328.13	1289.06
Indian Journal of Forensic Odontology		Semiannual	6500	6000	507.81	468.75
Indian Journal of Genetics and Molecular Research		Semiannual	8000	7500	625	585.94
Indian Journal of Law and Human Behavior		Semiannual	7000	6500	546.88	507.81
Indian Journal of Legal Medicine		Semiannual	9500	9000	742.19	703.13
Indian Journal of Library and Information Science		Triannual	10500	10000	820.31	781.25
Indian Journal of Maternal-Fetal & Neonatal Medicine		Semiannual	10500	10000	820.31	781.25
Indian Journal of Medical and Health Sciences		Semiannual	8000	7500	625	585.94
Indian Journal of Obstetrics and Gynecology		Quarterly	10500	10000	820.31	781.25
Indian Journal of Pathology: Research and Practice		Triannual	13000	12500	1015.63	976.56
Indian Journal of Plant and Soil		Semiannual	7500	7000	585.94	546.88
Indian Journal of Preventive Medicine		Semiannual	8000	7500	625	585.94
Indian Journal of Research in Anthropology		Semiannual	13500	13000	1054.69	1015.63
Indian Journal of Surgical Nursing		Triannual	6500	6000	507.81	468.75
Indian Journal of Trauma and Emergency Pediatrics		Quarterly	10500	10000	820.31	781.25
Indian Journal of Waste Management		Semiannual	10500	10000	820.31	781.25
International Journal of Food, Nutrition & Dietetics		Triannual	6500	6000	507.81	468.75
International Journal of Forensic Science		Semiannual	11000	10500	859.38	820.31
International Journal of Neurology and Neurosurgery		Quarterly	11500	11000	898.44	859.68
International Journal of Pediatric Nursing		Triannual	6500	6000	507.81	468.75
International Journal of Political Science		Semiannual	7000	6500	546.88	507.81
International Journal of Practical Nursing		Triannual	6500	6000	507.81	468.75
International Physiology		Triannual	8500	8000	664.06	625
Journal of Aeronautical Dentistry		Quarterly	8000	7500	625	585.94
Journal of Animal Feed Science and Technology		Semiannual	9000	8500	703.13	664.06
Journal of Cardiovascular Medicine and Surgery		Quarterly	11000	10500	859.38	820.31
Journal of Emergency and Trauma Nursing		Semiannual	6500	6000	507.81	468.75
Journal of Food Additives and Contaminants		Semiannual	6500	6000	507.81	468.75
Journal of Food Technology and Engineering		Semiannual	6000	5500	468.75	429.69
Journal of Forensic Chemistry and Toxicology		Semiannual	10500	10000	820.31	781.25
Journal of Global Medical Education and Research		Semiannual	7000	6500	546.88	507.81
Journal of Global Public Health		Semiannual	13000	12500	1015.63	976.56
Journal of Microbiology and Related Research		Semiannual	9500	9000	742.19	703.13
Journal of Nurse Midwifery and Maternal Health		Triannual	6500	6000	507.81	468.75
Journal of Orthopedic Education		Triannual	6500	6000	507.81	468.75
Journal of Pharmaceutical and Medicinal Chemistry		Semiannual	17500	17000	1367.19	1328.13
Journal of Plastic Surgery and Transplantation		Semiannual	27500	27000	2148.44	2109.38
Journal of Psychiatric Nursing		Triannual	6500	6000	507.81	468.75
Journal of Radiology		Semiannual	9000	8500	703.13	664.06
Journal of Social Welfare and Management		Quarterly	8500	8000	664.06	625
New Indian Journal of Surgery		Quarterly	9000	8500	703.13	664.06
Ophthalmology and Allied Sciences		Triannual	7000	6500	546.88	507.81
Pediatrics Education and Research		Quarterly	8500	8000	664.06	625
Physiotherapy and Occupational Therapy Journal		Quarterly	10000	9500	781.25	742.19
RFP Gastroenterology International		Semiannual	7000	6500	546.88	507.81
RFP Indian Journal of Hospital Infection		Semiannual	13500	13000	1054.69	1015.63
RFP Indian Journal of Medical Psychiatry		Semiannual	9000	8500	703.13	664.06
RFP Journal of Biochemistry and Biophysics		Semiannual	8000	7500	625	585.94
RFP Journal of Dermatology		Semiannual	6500	6000	507.81	468.75
RFP Journal of ENT and Allied Sciences		Semiannual	6500	6000	507.81	468.75
RFP Journal of Gerontology and Geriatric Nursing		Semiannual	6500	6000	507.81	468.75
RFP Journal of Hospital Administration		Semiannual	8000	7500	625	585.94
Urology, Nephrology and Andrology International		Semiannual	8500	8000	664.06	625

Terms of Supply:

1. Agency discount 12.5%. Issues will be sent directly to the end user, otherwise foreign rates will be charged.
2. All back volumes of all journals are available at current rates.
3. All journals are available free online with print order within the subscription period.
4. All legal disputes subject to Delhi jurisdiction.
5. Cancellations are not accepted orders once processed.
6. Demand draft/cheque should be issued in favour of "**Red Flower Publication Pvt. Ltd.**" payable at **Delhi**.
7. Full pre-payment is required. It can be done through online (<http://rfppl.co.in/subscribe.php?mid=7>).
8. No claims will be entertained if not reported within 6 months of the publishing date.
9. Orders and payments are to be sent to our office address as given below.
10. Postage & Handling is included in the subscription rates.
11. Subscription period is accepted on calendar year basis (i.e. Jan to Dec). However orders may be placed any time throughout the year.

Order from

Red Flower Publication Pvt. Ltd., 48/41-42, DSIDC, Pocket-II, Mayur Vihar Phase-I, Delhi - 110 091 (India)
Mobile: 8130750089, Phone: 91-11-79695648 E-mail: sales@rfppl.co.in, Website: www.rfppl.co.in

Pediatric Education and Research

Editor-in-Chief

Pravakar Mishra

Professor and Head of Pediatrics,
PRM Medical College Hospital,
Baripada, Odisha 757001, India.

National Editorial Board

Praveen Unki, Ballari, Karnataka

Abhijit Asaram Shinde, Ahmednagar, Maharashtra, India

Sunil Mhaske, Ahmednagar, Maharashtra, India

International Editorial Board

Ashnita Ashvini Krishna, Suva, Fiji, Islands

B. H. Nazma Yasmeen, Dhaka, Bangladesh

RED FLOWER PUBLICATION PVT. LTD.

Managing Editor

A. Lal

Publication Editor

Dinesh Kr. Kashyap

Pediatric Education and Research (PER) (pISSN: 2321-1644, eISSN: 2455-4871) is a quarterly peer reviewed journal. The journal is publishing original research, clinical observations, and special feature articles in the field of pediatrics, as broadly defined. Contributions pertinent to pediatrics are also included from related fields such as nutrition, surgery, dentistry, public health, child health services, human genetics, basic sciences, psychology, psychiatry, education, sociology, and nursing.

Abstracting and Indexing information: Index Copernicus, Gaudeamus Academia, Science Library Index, The International Committee of Medical Journal Editors (ICMJE).

Readership: Readership for Pediatric Education and Research includes pediatricians, researchers, pediatric investigators, and all those who diagnose and treat infants, children, and adolescents.

Subscription rates worldwide: Individuals - contact on 91-11-79695648 or mail to sales@rfppl.co.in; Institutional (annual) INR 8500/USD664.06. Payment methods: By Demand Draft/cheque should be in the name of **Red Flower Publication Pvt. Ltd.** payable at Delhi. By Bank Transfer/TT: **Bank name:** Bank of India, **IFSC Code:** BKID0006043, **Swift Code:** BKIDINBBDS. **Account Name:** Red Flower Publication Pvt. Ltd., Account Number: 604320110000467, Branch: Mayur Vihar Phase-I, Delhi - 110 091 (India).

© 2023 Red Flower Publication Pvt. Ltd. All rights reserved. The views and opinions expressed are of the authors and not of the **Pediatric Education and Research**. The **Pediatric Education and Research** does not guarantee directly or indirectly the quality or efficacy of any product or service featured in the the advertisement in the journal, which are purely commercial.

Red Flower Publication (P) Ltd.

Presents its Book Publications for sale

21. Recent Advances in Neonatology (2020)

Dr. T.M. Ananda Kesavam

INR 845/USD66

1. Beyond Medicine: A to E for Medical Professionals (2020)

Kalidas Chavhan

INR390/USD31

2. Biostatistical Methods For Medical Research (2019)

Sonjeet Sarmukhaldam

INR347/USD51

3. Breast Cancer: Biology, Prevention And Treatment (2015)

Dr. A. Ramesh Rao

INR299/USD23

4. Chhotanagpur A Hinterland of Tribes (2020)

Ambrish Gautam

INR347/USD45

5. Child Intelligence (2004)

Dr. Rajesh Shukla, Md, Deli.

INR659/USD51

6. Clinical Applied Physiology and Solutions (2020)

Varun Malhotra

INR299/USD23

7. Comprehensive Medical Pharmacology (2019)

Dr. Ahmad Najimi

INR460/USD34

8. Critical Care Nursing in Emergency Toxicology (2019)

Vivekanshu Verma

INR329/USD26

9. Digital Payment (Blue Print For Shining India) (2020)

Dr. Bishnu Prasad Patro

INR449/USD35

10. Drugs in Anesthesia (2020)

R. Varaprasad

INR395/USD46

11. Drugs In Anesthesia and Critical Care (2020)

Dr. Bhavana Gupta

INR325/USD104

12. MCQs in Medical Physiology (2019)

Dr. Bhawati Mehta

INR 399/USD49

13. MCQs in Microbiology, Biotechnology and Genetics (2020)

Biswajit Batabyal

INR 545/USD42

14. MCQs In Minimal Access and Bariatric Surgery (2nd Edition) (2020)

Aishuman Kanshal

INR 399/USD49

15. Patient Care Management (2019)

A.K. Mohiuddin

INR 599/USD44

16. Pediatrics Companion (2001)

Rajesh Shukla

INR 399/USD104

17. Pharmaceutics-1 (A Comprehensive Hand Book) (2021)

V. Sandilya

INR 399/USD49

18. Poultry Eggs of India (2020)

Prayfulla K. Mohanty

INR 399/USD30

19. Practical Emergency Trauma Toxicology Cases Workbook (2019)

Dr. Vivekanshu Verma, Dr. Shivo Rattan Kochhar, Dr. Devenatra Richharya

INR395/USD31

20. Practical Record Book of Forensic Medicine & Toxicology (2019)

Dr. Akhilesh K. Pathak

INR299/USD231

21. Recent Advances in Neonatology (2020)

Dr. T.M. Ananda Kesavam

INR347/USD45

22. Shipping Economics (2018)

Dr. D. Anitha

INR299/USD23

23. Skeletal and Structural Organizations of Human Body (2019)

Dr. D.R. Singh

INR659/USD51

24. Statistics In Genetic Data Analysis (2020)

S. Venkatasubramanian

INR299/USD23

25. Synopsis of Anesthesia (2019)

Dr. Lalit Gupta

INR1195/USD75

26. A Handbook of Outline of Plastic Surgery Exit Examination (2022)

Prof Ravei Kumar Chittoria & Dr. Saurabh Gupta

INR 498/USD 38

27. An Introductory Approach to Human Physiology (2021)

Satyajit Tripathy, Barsha Dassarma, Motilalpula Gibert Matsalisa

INR 599/USD 46

28. Biochemical and Pharmacological Variations in Venomous

Secretion of Toad (Bufo melanostictus)(2021)

INR 325/USD26

29. Climate, Prey & Predator Insect Population in Bt Cotton and

Non-Bt Cotton Agriculture Feilds of Warangal District (2022)

INR 325/USD26

30. Community Health Nursing Record Book Volume - I & II (2022)

Ritika Roque

INR 999/USD79

31. Handbook of Forest Terminologies (Volume I & II) (2022)

Dr. C.N.Hari Prasath, Dr. A. Balasubramanian, Dr. M. Sivaprakash,

INR 1325/USD104

32. MCQs of Biochemistry(2022)

Sachin C. Naravadija, Dr. Ifnana Begum

INR 399/USD49

33. Newborn Care in the State of Uttar Pradesh(2022)

Dr. Tridibesh Tripathy

INR 545/USD42

34. Osteoporosis: Weak Bone Disease(2022)

Dr. Dondeti Uday Kumar & Dr. R. B. Uppin

INR 399/USD49

35. Quick Updates in Anesthesia(2022)

Dr. Rupinder Kaur Kairch, Dr. Vibhagdhar Modak, Dr. Shilpa Samnakti

INR 599/USD44

36. Textbook of Practice of Medicine with Homoeopathic

Dr. Pramod Kumar

INR 399/USD49

37. Trends in Anthropological Research(2022)

Dr. Jyoti Ratan Ghosh,Dr. Rangya Gachui

INR 399/USD49

Order from: Red Flower Publication Pvt. Ltd., 48/41-42, DSIDC, Pocket-II,
Mayur Vihar Phase-I, Delhi - 110 091(India), Mobile: 8130750089,
Phone: 91-11-79695648, E-mail: info@rfpl.co.in, Website: www.rfpl.co.in

Pediatric Education and Research

May – August 2023
Volume 11 Number 2

Contents

Review Article

Prevention of Pediatric Burns Amrutha J.S, Ravi Kumar Chittoria, Barath Kumar Singh. P	49
A Review of Present and Emerging Treatment and Prevention Strategies for Bronchopulmonary Dysplasia in Preterm Neonates Sakshi Satish Rane, Abhijeet Shinde, Sunil Natha Mhaske	53

Case Report

Multiple Co-Infections in a Child with Beta Thalassemia Major: A Rare Case Report Mumtaz Sharif, Amit Saxena, Vinaykumar P Hedaginal, Divyani Dhole	71
Learning Disability in a Case of Primary Ciliary Dyskinesia: A Case Report Jagdish Taur, Praveen Unki, Santosh Kondekar, Suraksha Sharma, Qudsiya Ansari, Surbhi Rathi	77

Guidelines for Authors	82
-------------------------------	-----------

SUBSCRIPTION FORM

I want to renew/subscribe international class journal “**Pediatric Education and Research**” of Red Flower Publication Pvt. Ltd.

Subscription Rates:

- Institutional: **NIR 8500 / USD 664.06**

Name and complete address (in capitals): _____

Payment detail:

Online payment link: <http://rfppl.co.in/payment.php?mid=15>

Cheque/DD: Please send the US dollar check from outside India and INR check from India made payable to ‘Red Flower Publication Private Limited’. Drawn on Delhi branch.

Wire transfer/NEFT/RTGS:

Complete Bank Account No. 604320110000467

Beneficiary Name: Red Flower Publication Pvt. Ltd.

Bank & Branch Name: Bank of India; Mayur Vihar

MICR Code: 110013045

Branch Code: 6043

IFSC Code: BKID0006043 (used for RTGS and NEFT transactions)

Swift Code: BKIDINBBDS

Term and condition for supply of journals

1. Advance payment required by Demand Draft payable to **Red Flower Publication Pvt. Ltd.** payable at **Delhi**.
2. Cancellation not allowed except for duplicate payment.
3. Agents allowed 12.5% discount.
4. Claim must be made within six months from issue date.

Mail all orders to

Subscription and Marketing Manager

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091(India).

Phone: 91-11-79695648

Cell: +91-9821671871

E-mail: sales@rfppl.co.in

BHIM BOI UPI QR

SCAN HERE TO PAY
WITH ANY BHIM UPI APP



RED FLOWER PUBLICATIONS PRIVATE LIMITED

Prevention of Pediatric Burns

Amrutha J.S¹, Ravi Kumar Chittoria², Barath Kumar Singh. P³

How to cite this article:

Amrutha J.S, Ravi Kumar Chittoria, Barath Kumar Singh. P/Prevention of Pediatric Burns/Pediatr Edu Res. 2023;11(2): 49-51.

Abstract

This article discusses Indian burn prevention and first aid knowledge, attitudes, and practises. Rural and quasi-urban societies face preventative and first-aid issues. Poverty, over population, mysticism, and modernization coexist. This article on preventive measures should sensitise, educate, and foster communication between health care providers and the community. This could help provide clear and practical clinical guidelines for resource limited societies.

Keywords: Prevention; Pediatrics; Burns.

INTRODUCTION

This article discusses the knowledge, attitudes, and practises that exist among the Indian community with relation to the prevention of burns and the administration of first aid. Rural and quasi urban civilizations provide their own distinct set of obstacles in terms of disease prevention and first aid. There is a mix and coexistence of poverty, over population, mysticism, and modernization. With the help of this article, which provides recommendations for preventative measures, we expect that there will be more awareness, education, and understanding in both directions between members of the health care community and the community at large.¹ This could help in form the

formulation of therapeutic guidelines that are both clear and practical, making them suitable for the requirements of societies with little resources.

MATERIALS AND METHODS

This study was conducted in the Department of Plastic Surgery in a tertiary care institute. It is a review article based on 8 articles on pediatric burns after going through literature available in Scopus, PubMed, Google scholar & internet.

RESULTS

Based on the inclusion criteria 8 articles were studied to discuss Deep vein thrombosis under following headings:

1. Preventive Measures
2. Health Education
3. First Aid
4. Drawback
5. Social Media
6. Conclusion

Author's Affiliation: ^{1,3}Senior Resident, ²Professor, Department of Plastic Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, India.

Corresponding Author: Ravi Kumar Chittoria, Professor, Department of Plastic Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, India.

E-mail: drchittoria@yahoo.com

Received on: 13.03.2023

Accepted on: 15.04.2023

DISCUSSION

The data from the various open-source articles we have analysed and listed below for the prevention of pediatric burns. This article highlights that there are still several hazardous practices in the community, which can be addressed to reduce burn injuries.

Preventive Measures

The following recommendations for the prevention of pediatric burns are as follows.^{2,3}

1. Emphasizing the importance of cooking on an elevated platform.
2. Separate cooking areas from other living spaces.
3. Pouring bath water into cold water in a bucket before taking it to the bath area.
4. Supervising any fire related recreation.
5. Using LED or solar lamps instead of oil lamps.
6. Choosing cotton rather than silk or synthetic clothing for children are practical, realizable changes that could reduce the burn risk significantly.⁴
7. Health education at schools, Working place and community gatherings.
8. Applying cool running water to a burn and to stop drop and roll in case of a flame burn.
9. Precautious cooking if it was outside on a traditional wooden open fire.
10. Avoid using oil lamps on the floor.

Health Education

The major sources of first aid information were from school based health education, social and electronic media. These resources can be utilized to further disseminate knowledge on first aid and practical prevention technique. Studies show that a variety of factors such as socio-economic status, gender, age, social status, kind of disease, cost, availability, and access to services influence the decision to engage with a specific medical channel. Large-scale prevention campaigns and first-aid education via electronic and social media may result in positive change not only in awareness but also in application. Governments should seek local and international technical and financial assistance to explore affordable alternative energy resources.⁵

First Aid

Surface cooling with running tap water for 20

min is the current gold standard for first aid in burns. Documented benefits include eliminating noxious stimuli and wound progression, pain relief, decreasing oedema and infection thereby aiding epithelialization and reducing scarring. Despite the fact that many of those polled would use running tap water, only 8-12 percent achieved the recommended time of 20-30 min of cool running water.⁶

Draw backs

Home remedies for first aid, that people in the community thought acceptable. Some were harmless, but a few could cause further damage, be extremely painful and detrimental to healing. Survey confirms that approximately 80% of people continue to cook over traditional open wood fires. The awareness of general public regarding the various first aid for preventing pediatric burns is very limited.⁷

Social Media

Awareness videos in social media platforms like facebook, Instagram, whatsapp, Telegram, Twitter helps in reach out all populations and helps to educate the younger generation for the fruitful tomorrow.^{7,8}

CONCLUSION

The Preventive measures mentioned in the article can be applied in any mass health education programs. The above mentioned measures are easy to adapt and helps in preventing the burns with adequate knowledge.

REFERENCES

1. Understanding burn injuries in children – A step toward prevention and prompt first aid Aureen D’cunha a, Grace Rebekah b, John Mathai a , Susan Jehangir a, Department of Paediatric Surgery, Christian Medical College, Vellore, TN 632004 India b Department of Biostatistics, Christian Medical College, Vellore, TN 632004 India published in burns journal of Elsevier in 2021.
2. Sanghavi P, Bhalla K, Das V. Fire-related deaths in India in 2001: a retrospective analysis of data. Lancet 2009;373:12828.
3. Chong HP, Quinn L, Cooksey R, Molony D, Jeeves A, Lodge M, et al. Mortality in pediatric burns at the Women’s and Children’s Hospital (WCH), Adelaide, South Australia: 1960- 2017. Burns 2020;46 (February (1))20712.
4. Gupta M, Gupta OK, Goil P. Paediatric burns in

Jaipur, India: an epidemiological study. *Burns* 1992;18:637.

5. Light Timothy D, Latenser Barbara A, Heinle Jackie A, Stolpen Margaret S, Quinn Keely A, Ravindran Vinitha, et al. Demographics of pediatric burns in Vellore. *India J Burn Care Res* 2009;30(1):504.
6. Kalekhan F, Kudva AK, Raghu SV, Rao S, Hegde SK, Simon P, et al. Traditionally used natural products in preventing ionizing radiation-induced dermatitis: first review on the clinical studies. *Anticancer Agents Med Chem* 2021.
7. Bitter CC, Erickson TB. Management of burn injuries in the wilderness: lessons from low-resource settings. *Wilderness Environ Med* 2016;27(December (4))51925.
8. A. D'cunha, et al., Understanding burn injuries in children—A step toward prevention and prompt first aid, *Burns* (2021).

Pediatric Education and Research

Library Recommendation Form

If you would like to recommend this journal to your library, simply complete the form given below and return it to us. Please type or print the information clearly. We will forward a sample copy to your library, along with this recommendation card.

Please send a sample copy to:

Name of Librarian

Name of Library

Address of Library

Recommended by:

Your Name/ Title

Department

Address

Dear Librarian,

I would like to recommend that your library subscribe to the Pediatric Education and Research. I believe the major future uses of the journal for your library would provide:

1. Useful information for members of my specialty.
2. An excellent research aid.
3. An invaluable student resource.

I have a personal subscription and understand and appreciate the value an institutional subscription would mean to our staff.

Should the journal you're reading right now be a part of your University or institution's library? To have a free sample sent to your librarian, simply fill out and mail this today!

Stock Manager

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091(India)

Phone: 91-11-79695648

Cell: +91-9821671871

E-mail: info@rfppl.co.in

A Review of Present and Emerging Treatment and Prevention Strategies for Bronchopulmonary Dysplasia in Preterm Neonates

Sakshi Satish Rane¹, Abhijeet Shinde², Sunil Natha Mhaske³

How to cite this article:

Sakshi Satish Rane, Abhijeet Shinde, Sunil Natha Mhaske/A Review of Present and Emerging Treatment and Prevention Strategies for Bronchopulmonary Dysplasia in Preterm Neonates/Pediatr Edu Res. 2023;11(2): 53-68.

Abstract

Context: One of the most important chronic clinical conditions seen in preterm babies is Bronchopulmonary Dysplasia (BPD). With improvement in technology and available therapeutic options, the survival rates have dramatically improved over time, however, the incidence of BPD still continues to remain the same even today. The injury resulting in BPD likely begins as altered lung development before delivery in many infants and can be initiated by resuscitation at birth and then amplified by postnatal exposures. The multifactorial pathogenesis implicated in the development of BPD necessitates a multidimensional therapeutic approach, to manage all the complex manifestations of the disorder.

Aims: The presently used approaches for prevention as well as management are being used for more than a decade, and lack definite evidence. The aim of this literature review is to gather evidence on the presently available prevention and management approaches for bronchopulmonary dysplasia, as well as newer, promising therapeutic agents being experimented, in order to provide data to help optimize strategies in the NICU as well as OPD settings and help reduce the incidence of BPD and promote more definitive studies.

Methods and Materials: We carried out an extensive series of searches on PubMed database and tried to capture as many citations as possible for Bronchopulmonary dysplasia in preterm neonates, with peer-reviewed publications from 2000-2022. Approximately 96 studies, including animal studies, RCTs and systematic review and meta-analyses were considered. On-going experiments were queried from Clinical Trials.gov. The searches were carried out using the terms: "Bronchopulmonary dysplasia", "BPD", "Preterm neonates", "low birth weight", "pathogenesis", "diagnosis", "prevention", "treatment". Further manual assessment was also done to include other relevant publications.

Author's Affiliation: ¹3rd year MBBS Student, ²Associate Professor, ³Dean, Department of Pediatrics, Dr. Vithalrao Vikhe Patil Foundation's Medical College and Hospital, Ahmednagar 414111, Maharashtra, India.

Corresponding Author: Sakshi Satish Rane, 3rd year MBBS Student, Dr. Vithalrao Vikhe Patil Foundation's Medical College and Hospital, Ahmednagar 414111, Maharashtra, India.

E-mail: sakshi9rane@gmail.com

Received on: 29.03.2023

Accepted on: 17.04.2023

Results: Prevention of prematurity, systematic use of non-aggressive ventilator measures, avoiding supraphysiologic oxygen exposure and administration of surfactant, caffeine and vitamin A, antenatal glucocorticosteroids, and pharmacotherapeutics agents like diuretics, vasodilators, nitric oxide etc. can significantly reduce the risk of BPD development. MSC therapy, IGF-1 and clara cell protein administration are the most fascinating new measure to address the lung damage due to BPD.

Conclusion: Despite advancement in technology and availability of a myriad of treatment options, the multifactorial nature of BPD makes it a persistently challenging disorder to treat and even more so to prevent. While multiple therapies are used routinely either alone or in combination (potentially increasing drug-drug interactions and associated side effects), there is insufficient evidence supporting short and longer-term use of many of these agents. There is continued need for future meta-analyses and prospective randomized controlled studies designed to measure clinically meaningful outcomes, and an even greater need to design trials evaluating the safety, efficacy, and dosing of pharmacologic agents in this population. Stem cell treatment and other such innovative strategies may be the beginning of a new era in the treatment of BPD. New ways of preventing or modulating BPD are on the horizon, and will hopefully lead to continued improvement of long-term outcome of prematurely born infants.

Keywords: Neonates; Newer Therapies; Bronchopulmonary Dysplasia; Preterm; Prevention; Treatment.

INTRODUCTION

Bronchopulmonary Dysplasia (BPD)

Pre-maturity is known to be associated with a wide spectrum of respiratory disorders and both early and late complications are seen as a result. One of the most important chronic clinical conditions seen in these preterm babies is Bronchopulmonary Dysplasia (BPD).¹ Its implicated pathophysiology includes a confluence of pre and post natal factors, both of which contribute towards the interference in lung development, making BPD a long-term disorder with substantial morbidity.² With improvement in technology and available therapeutic options, the survival rates have dramatically improved over time, however, the incidence of BPD still continues to remain the same even today.³ While the exact incidence has been difficult to calculate due to the varying definitions for the disorder, studies show that based on how one defines BPD, the incidence can vary from 4% to 40%.⁴ The first definition of Bronchopulmonary dysplasia was given by Sheenan et al.⁵ in 1988, and it was: "the use of supplemental oxygen at 36 weeks PMA", later in 2001 an NIH consensus said that it is "the oxygen use for 28 days (not consecutive), with severity based on the amount of supplemental oxygen and mode of respiratory support at 36

weeks PMA" they further classified it into; mild (room air), moderate (<30% supplemental oxygen), severe (>=30% supplemental oxygen and/or positive pressure)." Walsh et al⁶ in 2004 defined it as the "receipt of positive pressure or supplemental oxygen at 36 weeks PMA. In infants receiving <=30% oxygen via hood or cannula, a stepwise room air challenge test is performed. Failure of the room air challenge or need for mechanical ventilation and/or positive pressure are classified as BPD."⁷ After a long gap, in 2017 a study published by Isayama et al defined it as "use of oxygen and/or respiratory support (including invasive and non-invasive support) at 40 weeks PMA."⁸ In 2018 an NICHD workshop concluded that BPD is "supplemental oxygen or positive pressure at 36 weeks PMA along with radiographic evidence of parenchymal lung disease, irrespective of prior duration of oxygen supplementation. It incorporates 3 grades of severity, depending on levels of supplemental oxygen and mode of support."⁹ The latest definition is however, the one published in a study by Jensen et al in 2019. It defines BPD as, "any respiratory support at 36 weeks PMA, irrespective of prior duration of or current level of oxygen therapy. It is further categorized according to disease severity: grade 1, nasal cannula at flow rates <=2L/min; grade 2, nasal cannulae at flow rates >2L/min or non-invasive positive pressure airway and grade 3, invasive mechanical ventilation.¹⁰

2 Types of BPD Old and New

BPD was not originally considered a lung development problem, but it was rather attributed to the damage done due to aggressive mechanical ventilation and oxygen toxicity on a mature lung lacking surfactant. This "old BPD", was diagnosed and described in premature babies as a chronic lung disease developing in those ventilated with high pressures and concentration of oxygen.¹¹ The pathological picture was classically characterized by areas of alveolar emphysema, atelectasis, inflammation, fibrosis, prominent airway injury and smooth muscle hyperplasia and hypertrophy resulting in a diffuse airway damage. This damage done can be ascribed to high concentrations of TNF-alpha and Macrophage inflammatory protein, Interleukin 1 beta, interleukin 6, which as seen following ventilation with high positive pressure and excessive volume, leading to inflammation and alveolar damage.¹² Antioxidant enzymes like catalase and copper zinc superoxide dismutase develop and mature in babies after inhalation of air after birth. Until then, reactive oxygen species are present in the lung, so even a small increase in these

oxygen species in preterm babies can cause lung damage.¹³ This was also shown in a study, where experimental animals exposed to high oxygen concentrations during early neonatal period showed findings of smooth muscle hypertrophy, oxidative stress and compromised alveolarization; all of which were also demonstrated in lung sections of premature babies who developed RDS and were subjected to aggressive ventilation.¹⁴

With improvement in the quality of care in NICUs, this "old BPD", is no longer seen, but is rather replaced by another form; the "new BPD". This is typically seen in extremely premature neonates who are born at the brink of viability and survive due to modern technology. The frequency of BPD increases with decrease in the gestational age of these babies.¹⁵ The pathophysiology of this form is attributed to multifactorial causation, involving both pre and postnatal factors that result in dysfunction of alveolar as well as vascular development. During the first few weeks of life, the lungs of very low birth weight babies are in the canalicular (17th to 26th week of gestation) or alveolar (27th to 36th week of gestation) phase of development. The respiratory bronchioles, pre capillaries and mucous glands in the bronchi are not completely developed, the interstitium has not thinned adequately to form the blood air barrier, and surfactant production by the lung epithelial cells has not started. Exposure to harmful stimuli can considerably disturb this vital morphogenesis. On histopathology, it is seen as a reduction in alveolarization with hypertrophied air spaces, immature or simple vascularization and inflammation and fibrosis.¹⁶ Further, the capillaries are decreased in number, and abnormal in shape and distribution. A study published by Jobe explained that "the injury resulting in BPD likely begins as altered lung development before delivery in many infants and can be initiated by resuscitation at birth and then amplified by postnatal exposures".¹⁷

Essentially, this new BPD is a due to a combination of prenatal factors such as placental abnormalities, IUGR, multiple births, chorioamnionitis and maternal smoking, as well as post natal factors that hinder lung development such as: mechanical ventilation and oxygen supplementation, post-natal steroids administration, infections (sepsis, necrotizing enterocolitis, lung infections etc), ventricular dysfunction, intracardiac shunts, or pulmonary vein stenosis.¹⁸ The role of genetic predisposition as well as mechanical trauma and oxygen toxicity should not entirely be dismissed either. The timing, type and duration of exposures,

together with the genetic characteristics of the child, influence the pattern of lung damage that can occur. The "new BPD thus, is far more severe than the old one in terms of alveolar and vascular damage and thus needs to be studied in greater detail.¹⁹

Factors Involved in the Development of BPD:

As previously discussed, the pathogenesis of BPD is multifactorial. However, some important pre and post natal factors that disturb the lung development either alone or in combination with other factors need to be defined and discussed. These factors include: prematurity, genetic predisposition, gender, mechanical ventilation and hyperoxia, infection and blood transfusion.

1. *Prematurity:* the most important risk factor for BPD is premature birth (gestational age of < 37 weeks). As discussed before, the lungs are in the canalicular and alveolar or saccular stage of development during this age and the immature lung is at most risk of damage if birth occurs during this time, due to surfactant deficiency and under developed antioxidant enzymes.²⁰
2. *Genetic predisposition:* A study by Bhandari et al used models and logistic regression to demonstrate statistically significant genetic predisposition for Bronchopulmonary dysplasia in twin births of less than 32 week gestation.²¹ Another study has shown that occurrence of BPD in first born twin, increases the risk of BPD in the subsequent twin.²²
3. *Gender:* Surfactant production occurs earlier in female fetuses and the delay in males is attributed to the effect of androgen. Some animal studies on mice, where long term androgen treatment was found to inhibit the surfactant protein gene expression in type 2 pneumocytes is proof of the same. Similarly, studies involving administration of estrogen to rabbits, showed increased surfactant production. Therefore, the early synthesis of surfactant means that the airflow rates and patency of airways is greater in females, which greatly reduces their risk to develop RDS. As physiological differences of gender are most likely not expressed in extreme prematurity, female gender does not remain protective in neonates born at 22-25 weeks.²³
4. *Mechanical ventilation:* High tidal volume during mechanical ventilation can cause over distension of small airways and alveoli and using insufficient positive end expiratory

pressures (PEEP) can cause repetitive opening and collapse of unstable lung unit which is injurious for alveolar capillary integrity. Also, high concentration of inspired oxygen (FiO₂) can cause oxidative stress and subsequent lung injury. A study by Albertine et al. compared two ventilation strategies to test the hypothesis that differences in tidal volume (VT) influence histopathologic outcome and found that slow, deep ventilation was associated with less atelectasis, less alveolar formation, and more elastin when compared with rapid, shallow ventilation. The avoidance of intubation and mechanical ventilation with the use of continuous positive airway pressure (CPAP) in the delivery room was associated with a lower incidence of BPD. Further a meta-analysis of six RCTs demonstrated that intubation and early surfactant followed by extubation to CPAP compared with later selective surfactant was associated with a lower incidence of mechanical ventilation, air-leak syndromes and BPD. Studies in animals have demonstrated that prolonged mechanical ventilation disrupted lung development and produced pulmonary histopathologic changes that were very similar to those seen in the lungs of preterm infants who die with BPD.²⁴

5. *Hyperoxia:* High concentrations of inspired oxygen can damage the lungs, although the exact level or duration of exposure that is unsafe is not known. Immature preterm lungs often are not capable of producing antioxidant enzymes like catalase and zinc super oxide dismutase, so reactive oxygen species like hydroxyl free radical, hydrogen peroxide etc cause greater cellular damage. This finding has been proven by animal studies, which showed similar patterns of lung injury in preterm neonates and mice exposed to hyperoxia. Since oxygen toxicity is indicated as a risk factor, many antioxidants are considered as a viable treatment option for BPD.²⁵
6. *Antenatal infection:* The risk of developing chorioamnionitis increased in extremely preterm babies. And the increased concentration of inflammatory mediators such as IL-6, IL-1 beta, TNF-alpha etc are responsible for the impaired lung development. Infection with *Ureaplasma urealyticum* has been shown to have a

significant inflammatory response in the body that greatly affects lung development in babies, leading to BPD.²⁶

7. *Postnatal infection:* Studies have shown increased risk of BPD in preterm neonates who were reported to have neonatal sepsis.²⁷
8. *Blood transfusion:* Increased level of free iron (which forms hydroxy 1 free radicals) as well as increased pulmonary blood flow and volume can trigger oxidative as well as mechanical damage in immature lungs and lead to progression of BPD.²⁸

Long Term Outcomes of BPD

The respiratory abnormalities that are seen in patients of BPD continue to manifest not only in childhood, but also in adolescence and adulthood. During school going years, children with BPD have greater cognitive, educational and behavioral issues than others, along with reduced lung function and fine and gross motor skills.²⁹ In adulthood, it manifests as early onset COPD, most likely due to impaired lung function which prevents most adults with BPD from exercising as much as the rest of the population. Parents of children diagnosed with BPD should ensure that they get enough exercise and do not indulge in smoking, especially during adolescence.³⁰ While it is difficult to exactly point out the long term outcomes of BPD, as most of the adults with BPD have received older forms of treatment, but it is still clear that BPD, due to its association with lung function impairment, greatly reduces the quality of life of patients.

Structural and functional alterations of the respiratory tract, increased risk of hospital readmission, respiratory infections and asthma as well as lung arterial hypertension are frequently noted as the most common long term outcomes of preterm neonates with BPD.

1. *Structural alteration of the respiratory tract:* Patients of both old as well as new BPD share this feature of physical damage to the lungs due to aggressive ventilation. The incidence is however, comparatively more in old BPD. Studies have shown that patients with BPD show considerable abnormalities on chest CT scans. Linear and triangular subpleural opacities and hyperlucent areas are seen on most of the scans and it is associated with the duration of oxygenation, despite improvements in the quality of care over time.³¹
2. *Functional alterations of the respiratory tract:*

All patients of BPD show notable functional alterations of the lower respiratory tract which worsens in adulthood. A study conducted on the same showed that that 68% of the subjects with BPD had airway problems [lower forced vital capacity (FVC), lower forced expiratory volume in 1s (FEV1) and lower forced expiratory flow between 25 and 75% of vital capacity (FEF25%-75%) than individuals included in the preterm group without BPD and term controls. Further more, 24% of the subjects with old BPD had fixed airway obstruction, and 52% had reactive airway disease, as indicated by their responses to the administration of methacholine or a bronchodilator. It was also reported that Although lung volumes increased with time, persistent flow limitation was evidenced. At 6, 12 and 24 months, low partial expiratory airflow, measured by maximum flow at functional residual capacity (V_{max} FRC), was shown, without any significant increase over time.³²

3. *Hospital readmission:* It has already been proven that preterm neonates are more likely to be re-hospitalized than term neonates. That risk is even greater if they develop BPD. Despite pre and post natal preventive measures, infants who receive oxygenation and develop BPD have a higher rate of readmission to hospitals. It is also proved by a study which estimated the rate of re-hospitalization in extremely preterm babies during their first 9 months post discharge and found that 47.3% patients were readmitted atleast once and over half of these were respiratory disorders.³³
4. *Respiratory tract infections:* Preterm neonates suffer from respiratory infections more than term neonates and that risk is higher if they also suffer from BPD. The already damaged lung in these patients stands at a higher risk of further damage and hence longer duration of hospitalization as evidenced by most studies.³⁴
5. *Asthma:* It has been seen that children born preterm and diagnosed with BPD, at 11 years of age suffered from clinically evident asthma in 25% of cases. Children with BPD have neutrophilic airway inflammation and lower values of exhaled nitric oxide and exhaled breath temperature. The airway obstruction is only partially reversed by beta 2-agonists, the response to inhaled corticosteroids is

poorer, and the acute exacerbations are fewer because patients with BPD suffer from fixed airway narrowing.³⁵ Children with BPD might be intolerant to exercise due to abnormal bronchial function. Karila et al. reported that children with BPD examined at 7–14 years old had ventilatory limitations on exercise, with greater use of the ventilatory reserves ($p < 0.01$) and lower maximal ventilation ($p < 0.01$) and tidal volume ($p = 0.01$). Moreover, changes in ventilation ($p < 0.0001$) and tidal volume ($p = 0.003$) during exercise were significantly smaller in the BPD group than in controls.³⁶

6. *Lung arterial hypertension:* Lung arterial hypertension is a result of vascular development anomalies that develop alongside lung development anomalies. Studies have shown that this complication can be seen in around 17% diseases, irrespective of the grade of severity, but is more commonly found in moderate severe disease. Pulmonary arterial hypertension needs to be diagnosed early on, and while cardiac catheterization is a gold standard investigation, transthoracic echocardiography is mostly used in infants as it is non-invasive, and has a diagnostic accuracy of 79% for incidence and 47% for severity.³⁷ Management of these patients if focused on vasodilation to reduce the pressure and includes drugs such as oral sildenafil (drug of choice), prostacyclin analogues, intravenous phosphodiesterase III inhibitors and nitric oxide. Nitric oxide is particularly advised in preterm infants with associated complications such as PROM, oligohydramnios, and pulmonary hypoplasia.³⁸

Why We are Writing this Review

The multifactorial pathogenesis implicated in the development of BPD necessitates a multidimensional therapeutic approach, to manage all the complex manifestations of the disorder. A team of clinicians is needed to not only manage the condition on NICUs, but also to focus on prevention where possible. The presently used approaches for prevention as well as management are being used for more than a decade, and lack definite evidence. More studies need to be performed that show a positive outcome and a significant decrease in the incidence of BPD. In this review, we will discuss all therapies in use currently with appropriate evidence as well as introduce certain newer

therapies under research.

MATERIALS AND METHODS

The aim of this literature review is to gather evidence on the presently available prevention and management approaches for bronchopulmonary dysplasia, as well as newer, promising therapeutic agents being experimented, in order to provide data to help optimize strategies in the NICU as well as OPD settings and help reduce the incidence of BPD and promote more definitive studies.

We carried out an extensive series of searches on Pub Med database and tried to capture as many citations as possible for Bronchopulmonary dysplasia in preterm neonates, with peer-reviewed publications from 1996-2022. Approximately 96 studies, including animal studies, RCTs and systematic review and meta-analyses were considered. On going experiments were queried from Clinical Trials.gov. The searches were carried out using the terms: "Bronchopulmonary dysplasia", "BPD", "Preterm neonates", "low birth weight", "pathogenesis", "diagnosis", "prevention", "treatment". Further manual assessment was also done to include other relevant publications.

Current Treatment and Prevention Strategies

Ventilation:

While BPD is a multifactorial disease, one of the most important risk factors still remains mechanical ventilation. The last decade has witnessed the concept of delivery room stabilization where nasal continuous positive airway pressure (CPAP) has been increasingly used to manage preterm infants <1,500 g birth weight in the delivery room and the first few days in the neonatal intensive care unit. This has however not affected the number of neonates needing mechanical ventilation.³⁹ Hence, ventilation remains an important treatment modality but comes with its set of challenges. In ventilated preterm infants, permissive hypercapnia with a partial pressure of CO₂ in the arterial blood (PaCO₂) between 45 and 55 mmHg and a pH > 7.20 has been suggested to avoid high tidal volumes and lung over inflation. However, no strong advantage of the same has been established.⁴⁰ As previously described, mechanical ventilation via an endotracheal tube exposes the developing lung to volutrauma and barotraumas which lead to lung fibrosis and inflammation and thus BPD. Also, weaning infants with BPD from mechanical ventilation is difficult and has to be accomplished

gradually. When the patient is able to maintain an acceptable arterial oxygen partial pressure (PaO₂) and arterial carbon dioxide partial pressure (PaCO₂), with peak inspiratory pressures between 15 and 18 cm H₂O and a fraction of inspired oxygen (FiO₂) lower than 0.4, extubation should be attempted. As long as the pH is within acceptable limits, a certain degree of hypercapnia must be tolerated after these patients are taken off the ventilator.⁴¹

Non-invasive management strategies, in which infants receive respiratory support without the need for an endotracheal tube, have been studied as a strategy to avoid direct trauma to the developing lung, and potentially reduce the risk of developing BPD. The various non-invasive respiratory ventilation strategies that have been adopted, include the use of non-invasive positive pressure ventilation (NIPPV), nasal continuous positive airway pressure (NCPAP) and high flow nasal cannulas (HFNCs). Studies which compared differences between ventilation with and without an endotracheal tube have shown that avoiding the tube had a small but significant beneficial impact in preventing BPD (OR 0.83; 95% CI 0.71-0.96). Indicating that these methods can be used in neonates to prevent development of BPD. However, the best non-invasive method to decrease the development of BPD has not been defined. Several studies as well as two meta-analysis have reached the conclusion that no difference in respiratory failure or need for intubation was seen between NIPPV and NCPAP.⁴²

The use of high-frequency ventilation has also been recommended as a way to prevent ventilator associated lung injury, but the data is insufficient and studies which focused on trying to find association between first intention high frequency ventilation and reduction of barotrauma and volutrauma found no significant difference in the outcome of death or BPD. Even when compared with conventional ventilation, the difference was small and inconsistent.⁴³ Lung protective ventilation therefore remains an important intervention available to clinicians. Another new strategy in ventilation of preterm infants is volume targeted ventilation. A study by Wheeler et al. showed that infants ventilated using volume targeted ventilation had reduced death or BPD compared with infants ventilated using traditional pressure limited ventilation. Similar findings were seen in other studies where volume targeted ventilation is physiologically more logical than pressure limited ventilation, and is associated with a reduced risk of pneumothorax, hypocapnia, duration of ventilation,

death or BPD, and severe intra ventricular hemorrhage. Therefore, it should now be adopted as the main mode for mechanical ventilation of preterm neonates.⁴⁴

Oxygenation:

As hyperoxia has been implicated in the development of BPD, a large number of studies have been conducted to find conclusive evidence and lay out guidelines for the optimal range of oxygen saturation to be used in preterm infants, with little merit. A multicenter, double blind, randomized, controlled trial with 358 infants born at <30 weeks, shown no significant differences according to weight, length, or head circumference at a corrected age of 12 months between the groups with standard saturation (oxygen saturation range 91–94%) and high saturation (oxygen saturation range 95–98%).⁴⁵ The frequency of major developmental abnormalities also did not differ significantly between the standard saturation group and the high saturation group. Another STOP-ROP study has in a 5-year period shown a higher incidence of BPD and longer hospitalization of infants with oxygen saturation of 96–99% compared with oxygen saturation of 89–94 %.⁴⁶

Studies have shown that a lower target range of oxygenation (85–89%), as compared with a higher range (91–95%), did not significantly decrease the composite outcome of severe retinopathy or death, but it resulted in an increase in mortality and a substantial decrease in severe retinopathy among survivors. However, the incidence of BPD is reduced in the lower oxygen saturation group as compared with the higher oxygen saturation group.⁴⁷ A recent evaluation of five randomized, controlled trials including more than 4800 infants, in whom lower (85–89%) versus higher (91–95%) SpO₂ targets were compared, concluded that the lower target range did not reduce BPD, severe visual problems or rate of disability at 12–24 months. By contrast, it was associated with increased risks of death and necrotizing enterocolitis. Some authors have indicated that, in the first few minutes of life, SpO₂ of 70–80% might be acceptable. However, after 5 min, SpO₂ must be maintained at between 88 and 92% with a higher alarm limit of 96%. Slightly higher SpO₂ can be tolerated for MPT patients for whom the alarm limit of 97–98% can be accepted. However, more studies need to be conducted to form perfect guidelines.⁴⁸

Surfactant:

Surfactant deficiency in premature neonates leads to increased surface tension and reduced

pulmonary compliance. Thus, exogenous surfactant administration is one of the most important ways of reducing preterm infant mortality and modifying characteristics of BPD. Older studies have shown that antenatal corticosteroids coupled with postnatal exogenous surfactant administration significantly reduces incidence of BPD. However, newer analysis have refuted these claims. However it is indicated that the time and manner of administration of the surfactant may play a significant role. Early surfactant administration permits immediate extubation to less aggressive ventilator measures, thus reducing the risk of BPD development.⁴⁹

Surfactant administration is done after intubation and is followed by mechanical ventilation which circles back to ventilator associated lung injury and higher risk of BPD. To circumvent this problem, the INSURE (Intubation Surfactant Extubation) technique of surfactant administration by transient intubation, surfactant administration, and immediate extubation can be tried. It allows medication delivery without excessive lung injury. However, trials comparing INSURE to CPAP found no difference in reduction in incidence or mortality between the two.⁵⁰ The IN-REC-SURE (INTubate, RECRuit-SURfactant-Extubate) trial was recently published which compared surfactant administration after alveoli recruitment using high frequency oscillatory ventilation, followed by extubation with the traditional INSURE method in preterm infants who failed nasal CPAP. Although there was a reduced requirement for mechanical ventilation during the first 72 hours of age in the IN-REC-SUR-E (40%) group, no difference was found between the two groups in the incidence of moderate to severe BPD.⁵¹ In order to entirely eliminate the mechanical ventilation factor, administration of surfactant has been tried using catheters. When compared to standard administration of surfactant through an endotracheal tube it was found to be associated with decreased risk of BPD (RR 0.71, 95% CI 0.52–0.99), BPD or death (RR 0.74, 95% CI 0.58–0.94), and need for invasive ventilation (RR 0.67, 95% CI 0.53–0.84). Aerosolized surfactant have also been evaluated as a less invasive alternate route of surfactant administration and similar findings have been reported.⁵²

Corticosteroids:

Inflammation in lungs has been known to be the major culprit of acute lung injury, so it only makes sense to use corticosteroids in the treatment of BPD. Antenatal corticosteroids are indicated for women at risk of preterm delivery as they decrease

the risk of RDS. Studies have shown that antenatal glucocorticosteroids have decreased the incidence of RDS by as high as 50%, but they have not impacted the incidence of BPD. This can be due to early lung maturation induced by these drugs, but no or deleterious effect on alveolarization. Animal studies have shown similar findings. Maternal glucocorticoid treatment has both an acute and a chronic effect on fetal monkey lung. A maternal dose of 0.3 mg/kg betamethasone before preterm delivery at 133 days gestation caused mesenchymal thinning and a large increase in maximal lung gas volumes, with minimal effect on surfactant phospholipids. When the fetuses were delivered close to term at 160 days gestation, however, the alveolar number, lung surface area and lung gas volume expressed per kilogram body weight were decreased.⁵³

Postnatal corticosteroids: Systemic: Reviews have shown that dexamethasone facilitates extubation, reduces the combined endpoint of death or BPD at 28 days or 36 weeks PMA, and also reduces the incidence of PDA and ROP. However trials where glucocorticoids have been used early in life have also found a significant increase in adverse long term neurologic outcomes like cerebral palsy. There has however been no significant increase in long term neurologic outcomes detected with regard to moderately early and late administration of glucocorticoids some other studies state that moderately early administration of dexamethasone (7-14 days after birth) did not significantly increase the combined outcome of death or cerebral palsy and actually showed a dose dependent decrease (6.2%) in cerebral palsy with each incremental mg/kg increase in cumulative dexamethasone dose which was not demonstrated in delayed trials. These data illustrate the potential time sensitive effects of dexamethasone and the need for clinicians to balance the known impact on neurodevelopmental outcome associated with prolonged mechanical ventilation and the development of BPD with the risks/benefits of systemic glucocorticoid treatment.⁵⁴

Other investigators have suggested that a primary cortisol deficiency in preterm infants increases the risk of BPD which may be amenable to early treatment with a less potent corticosteroid such as hydrocortisone. Infants who received hydrocortisone however did not demonstrate a significant reduction in mortality, BPD, or cerebral palsy and actually had a significant increase in the incidence of gastrointestinal perforation which occurred more often with concurrent indomethacin

administration.⁵⁵

Inhaled: Inhaled steroids have been suggested to promote respiratory benefits while also reducing systemic side effects. Studies examining the benefits of inhaled corticosteroids administered early or late have not been able to demonstrate any impact of inhaled corticosteroids respiratory status. Further, the potential for systemic absorption of inhaled steroids and subsequent side effects (e.g., growth, adrenal suppression, etc.) remains an issue. Further research is needed to evaluate the perfect strategy for inhaled steroid administration.⁵⁶

Caffeine:

Caffeine is a mainstay of treatment in most NICUs, and is used to prevent apnea of prematurity and BPD. While its mechanism of action is not entirely known, it is said that it may have anti-inflammatory properties. The standard dose of caffeine citrate is 20 mg/kg for loading and 5-10 mg/kg for daily maintenance. It has been shown to increase pulmonary compliance and reducing airway resistance. Also, it infants show more diaphragm contractility and respiratory drive, which facilitates early extubation.⁵⁷ Also, the famous Caffeine for Apnea of Prematurity study showed that caffeine administration was associated with a significant reduction in BPD development and reduced neurodisability at 18 months of age.⁵⁸ Other studies have also shown similar findings, where infants in the treatment group had significantly less apnea of prematurity, and were also noted to have less BPD, patent ductus arteriosus (PDA), and cerebral palsy when followed out to 18-21 months corrected gestational age. However, these outcomes were limited to short term benefits.⁵⁹

Further studies which compared the timing of administration of caffeine, showed improved outcomes with early caffeine therapy, with 25% of infants who received early caffeine developing the outcome of death or BPD compared to 53% of infants in the late caffeine group. Another study showed that administration of caffeine within the first 2 days of life seems to lead to a reduced risk of BPD compared to later administration (OR 0.69; 95% CI 0.58-0.82; p <0.001), although it was found to be associated with an increased risk of necrotizing enterocolitis (OR 1.41; 95% CI 1.04-1.91; p = 0.027). Present research thus concludes that caffeine should remain the mainstay of treatment especially when initiated within the first week of life for prevention of development of BPD.⁶⁰

PDA Closure:

Studies have shown that presence of a PDA is

associated with the development of BPD, but it has not proven to be causative. The mechanism of left to right shunting observed across a patent ductus arteriosus can worsen pulmonary congestion and edema, further compromising alveolar development. Randomized controlled trials evaluating ductal closure however, have failed to show a reduction a risk of BPD.⁶¹

An RCT which was evaluating PDA closure with indomethacin or surgical ligation compared to no intervention, found lower rates of BPD in the later group ($p<0.05$) with no difference in mortality or morbidity. Another study examining ibuprofen treatment concluded on similar lines. These studies however, focus on treatment of BPD and not the prevention. Trials like the PDA-Tolerate trial compared the timing of PDA closure and its effect on BPD. It compared early with later conservative pharmacologic treatment of moderate to large PDA in infants who had on going respiratory support needs and had a moderate to large PDA, there was a higher incidence of BPD in those intubated >10 days (75%) compared to infants intubated <10 days (27%, $p<0.0001$). However, among the infants intubated greater than 10 days, prolonged exposure to moderate-to-large PDA was associated with increased risk of BPD ($p=0.04$). These findings suggest that an increased risk of BPD among infants with exposure to moderate-to-large PDA and receiving prolonged mechanical ventilation >10 days.⁶²

Due to lack of definitive proof, most centres prefer non-intervention and conservative management. However, it is prudent to note that a subset infants <28 weeks with moderate severe PDA might likely benefit from PDA closure as spontaneous closure is delayed and it can decrease the incidence and mortality associated with BPD.⁶³

Diuretics:

Excessive intravenous fluids used to provide nutrition and hydration to preterm neonates, often results in pulmonary edema, which can warrant a need for external respiratory support and thus cause BPD. So, clinicians often use diuretics with the goal of decreasing pulmonary edema and the amount of respiratory support needed, thereby improving risk factors leading to the development of BPD. Various independent studies have shown that diuretics are associated with improved lung compliance and decreased resistance. Loop diuretics such as Furosemide are considered the treatment of choice. Several studies have demonstrated alternate day, daily, and even aerosolized furosemide improve clinical respiratory

status, pulmonary mechanics, oxygenation, and facilitate weaning from mechanical ventilation. Furosemide also decreases interstitial edema and vascular resistance.⁶⁴ A study conducted on infants born at 23-29 weeks gestational age, who were exposed to diuretics between first 9 weeks of life, an increased exposure to furosemide therapy by 10% significantly reduced the incidence of BPD (4.6%; $p=0.001$) or death due to the same (3.7%; $p=0.01$). A review of 6 RCTs concluded that a decreased risk of failure to extubate within a week of furosemide usage and improvement in pulmonary compliance with a one-to-two-day course of furosemide was seen. However, long term benefits of this treatment have not yet been observed. So while the short term improvement is a plus, a number of side effects of long term use of diuretics like electrolyte disturbances, ototoxicity and azotemia are also known occur.⁶⁵ Also, an observational cohort (the Prematurity and Respiratory Outcomes Program) showed no association between diuretic use and change in respiratory outcomes. It is also pertinent to note that other classes of diuretics like Thiazides and Spironolactone have not been as extensively studied, and the small number of studies which have been performed have not shown any promising results in terms of duration of hospitalization or ventilation. So they are not recommended as treatment.⁶⁶

As of now, there are no standard guidelines in place that suggest the chronic use of loop diuretics in preterm neonates with BPD, and studies comparing centres using diuretics verus those who don't use them, found no differences in mortality. So more studies need to be designed to establish protocol for diuretic therapy and clear the conflict related to benefits versus long term side effects.

Bronchodilators:

A majority of the clinical trials have been performed using inhaled bronchodilators like Salbutamol (inhaled Beta 2 agonist) and Ipratropium bromide (muscarinic antagonist), which produce bronchodilation and thus improve lung compliance and decrease airway resistance.

Salbutamol is indicated where strong reversible bronchospasm is present, where as ipratropium bromide has been recommended in chronically ventilated infants with BPD, either singly or in combination with salbutamol. However, while acute exacerbation of symptoms are managed effectively by these agents, trials have failed to demonstrate any improvement in the severity or progression of BPD. Although a few studies have shown improvement in lung function with

Salbutamol, others have questioned its long-term efficacy and pointed out that tolerance develops with its prolonged use.⁶⁷

Despite this data, hospitals prefer prescribing a trial of salbutamol with addition of ipratropium bromide if improvements are not seen in neonates who develop wheezing or severe BPD. The trend and manner of this exposure varies between centres however. This lack of conclusive evidence to strongly support inhaled bronchodilator use in hospitalized infants warrants more research.⁶⁸

Nitric Oxide:

While the use of inhaled nitric oxide is common in the treatment of acute hypoxaemic respiratory failure and pulmonary hypertension in term neonates, its use in the prevention of BPD in preterm babies has proven to be unsuccessful. Studies which focused on administration of this gas early or later after birth have shown no significant effect, and so it is not a preferred modality for treatment when administered alone. However, when given alongside intramuscular injections of Vitamin A, a statistically significant reduction in not only mortality and neurocognitive morbidity but also incidence of BPD was observed in low birth weight preterm infants.⁶⁹

Vitamin A:

Vitamin A or retinol plays a role in the normal development of epithelium of the respiratory tract as well as in promoting tissue repair. More over multiple studies showed that deficiency of Vitamin A in preterm LBW babies leads to more risk of BPD development. A recent meta-analysis of studies showed that preterm neonates treated with vitamin A had a lower risk of BPD. However, the reduction in risk was small and observed only in children weighing <1000 g. Vitamin A also does not reduce mortality or neurodevelopmental morbidity and the need for ventilation.⁷⁰

Also, the best route of administration is not yet clear. As an exploration for alternate routes of administration, a recent RCT of 188 infants born less than 28 weeks gestation evaluated enterally administered vitamin A compared to intramuscular. While it was found that following enteral treatment plasma retinol levels increased, there was no improvement in severity of BPD. So, it was suggested that the administration of vitamin A to preterm infants should be done after considering both advantages and problems as intramuscular administration is painful and needs to be repeated multiple times which increases risk of sepsis.⁷¹

Antioxidants:

As discussed previously, due to immature antioxidant enzymes in preterm lungs, they are more prone to oxidative stress induced by reactive oxygen species. The concentration of these ROS is increased in premature lungs especially in the first week of life and results in chronic lung damage. These reactive oxygen species which are toxic to the lung tissue are not only produced by infection and inflammation, but the treatment modalities that we use like oxygen supplementation (results in hyperoxia), blood transfusion (reperfusion injury) and ventilation associated inflammation also contribute towards their production. A study conducted by Davis et al in 1997 and followed up in 2000, showed that antioxidant enzyme replacement therapy in high risk very low birth weight preterm neonates via intratracheal administration of recombinant human Cu/Zn SOD is associated with lower levels of biomarkers of acute lung injury, but there is no difference in morbidity or mortality.⁷² However, when a larger trial was later conducted, it showed a reduction in pulmonary morbidity in the treatment group as compared to the placebo group. This shows that more larger trials need to be conducted and the effect of antioxidant enzyme replacement on lung injury outcomes cannot be totally negated.⁷³

Infection prevention and antibiotic stewardship:

As previously discussed, ureaplasma infection has been associated with the development of BPD. Macrolides not only treat the infection, but are also anti-inflammatory and so are thought to be a potential agent for both the prevention as well as management of BPD. However, trials with prophylactic azithromycin therapy have not found much effectiveness and an RCT including IV azithromycin therapy showed that ureaplasma can be eradicated from the respiratory tract, but it does not change the incidence of BPD. Further, it is known that antibiotics used to treat infections, can further increase the risk of development of BPD, as proven by a study where, early empiric antibiotic therapy of 4-7 days is associated with increased adjusted odds of BPD, and each additional day of antibiotics in the first 2 weeks of age significantly increases the risk of severe BPD (or 1.15, 95% CI 1.08-1.27).⁷⁴ Similar findings were seen in other studies evaluating antibiotic exposure and risk of BPD. These nosocomial infections that result in inflammatory mediators can easily be prevented by quality control and strict hand hygiene policies. Nosocomial infections reduce by 8% by simple quality control measures. Pros and cons of antibiotic use need to be weighed and

effective antibiotic stewardship policies need to be set in place. At present, larger trials need to be conducted to ascertain the efficacy of prophylactic antibiotic therapy, but until then, some centres report screening extremely premature infants for *Ureaplasma* soon after birth, and selectively treating those infants requiring prolonged mechanical ventilation with azithromycin.⁷⁵

Role of nursing:

Close monitoring is important, as infants with BPD are susceptible to lower respiratory tract infections, hypertension and respiratory failure. Daily measurement of body weight, without clothes and with the same scales, is required in order to determine weight changes. Assessment of the child's respiratory and fluid status, skin color, breathing effort and abnormal sounds of breathing, chest retraction, capillary filling time, secretions, vital signs and edema every 1-4 hrs is important. Any deviation from the baseline is required to be reported. Fluid intake and output should be carefully monitored in order to maintain adequate hydration, along with regular assessment of electrolyte levels and an increased fluid intake, if no contraindications exist. Infants should be fed over a long time interval after which the infants need to be held in an upright position in order to enable them to burp. Feeding through a nasogastric (NG) tube, whenever required, particularly at night, and checking the placement of the NG tube prior to feeding to avoid aspiration are important care-taking steps in the management of BPD.

Chest physiotherapy is required every 4 h as tolerated, suction should be performed 4 times per day as and when required and oxygen should be administered if necessary. Chest physiotherapy and suctioning help to remove mucus from the airways and lungs. The condition of the skin surface should be monitored if required. Bronchodilators should be administered to increase the airflow to the alveoli and diuretics should be added to reduce the risk of fluid retention and pulmonary edema, thereby improving the respiratory function. Regular care of the child with regard to bathing, clearing the airways and maintaining the skin is important along with informing parents about the details of the treatment and care of the baby with follow-up instructions.⁷⁶

Emerging areas of research

Stem cells

Evidence suggests that stem and progenitor cell impairment can favour BPD development. So it has been hypothesized that the use of exogenous

stem or progenitor cells could protect or regenerate even a damaged lung as stem cells contribute to organogenesis and growth and also contribute to organ repair and regeneration throughout life. Mesenchymal stromal cells (MSCs) are the most extensively studied cells because of their ease of isolation and culture and their pleiotropic effects (anti-inflammatory, pro-angiogenic, anti-apoptotic, anti-oxidant, and anti-fibrotic activities). A great number of animal studies have used lung resident mesenchymal stem or progenitor cells (MSCs) in BPD model. Research suggests that MSCs are an important component of the parenchymal progenitor cell niche and orchestrate organ homeostasis and repair following injury.⁷⁷

In animal models, treatment with MSCs was shown to reverse alveolar injury and improve lung functioning. MSC derived extracellular vesicles have pro-regenerative and immune modulating effects and have been shown to improve lung morphology, pulmonary function and suppress inflammation in animal models. Chang et al. assessed the safety and feasibility of a single, intratracheal transplant of human umbilical cord blood derived MSCs in preterm infants. Administration of both low and high doses of cells was well tolerated and the respiratory severity score measured after transplantation was significantly lower than in controls. MSCs were also found to be safe and well tolerated in adult patients. No evidence of pro-fibrotic and tumorigenic potential of MSCs was reported. These results of MSC administration are noteworthy but more clinical trials need to be performed for defining exact guidelines. Further larger scale MSC transplantation remains a challenge.⁷⁸

IGF1:

Insulin like growth factor which rises during the third trimester of pregnancy is associated with vascular development. The levels of IGF-1 are low in preterm neonates. IGF-1 is upregulated by insulin and so hyperglycemia is common in preterm neonates. Due to lower levels of IGF-1, preterm babies are known to have less weight gain, increased respiratory distress, retinopathy of prematurity and necrotizing enterocolitis. Studies have shown that early insulin treatment during the first week of life induces a late increase in IGF-1 levels between days 7 and 28 of life, improved weight gain, and may improve the outcomes of these infants. Intravenous infusion of recombinant human IGF-1 complexed with its binding protein recombinant human IGFBP-3 (rhIGF-1/rhIGFBP-3) has been investigated as a therapy since IGF-

1 replacement in extremely preterm infants has been demonstrated to be safe and well tolerated. This potential needs to be better tapped into as a treatment option and more clinical trials need to be performed to draw conclusive evidence and create guidelines.⁷⁹

Clara proteins

CC10 is a protein secreted by non-ciliated bronchiolar epithelial cells (club cells) and is one of the most abundant proteins within the fluid lining the lung epithelium. It is a major secretory protein. CC10 binds to lipid components of the pulmonary surfactant such as phosphatidylcholine and phosphatidylinositol, suggesting that it may transport or protect these phospholipids from degradation. It also negatively regulates airway inflammatory responses and also regulates surfactant phospholipids catabolism. It also has anti-inflammatory properties. It is lower in tracheal aspirates of premature infants who subsequently died or developed BPD. Animal studies have demonstrated that administration of recombinant human CC10 (rhCC10) showed a significant rhCC10 dose dependent increase in respiratory compliance and ventilation efficiency index. Early intervention with rhCC10 up-regulates surfactant proteins and vascular endothelial growth factor expression. This finding suggests that CC10 can protect against hyperoxia and mechanical ventilation in the immature lung. Further larger scale studies and clinical trials in NICUs are warranted to determine its effectiveness in hospital settings.⁸⁰

CONCLUSION

Despite advancement in technology and availability of a myriad of treatment options, the multifactorial nature of BPD makes it a persistently challenging disorder to treat and even more so to prevent. While the understanding of the pathogenesis of BPD has increased a lot, what continues to remain a challenge is reducing its incidence and thus the economic as well as social and physical burden on health systems and families.⁸¹ While multiple therapies are used routinely either alone or in combination (potentially increasing drug-drug interactions and associated side effects), there is insufficient evidence supporting short and longer term use of many of these agents. In fact, no single therapy has been shown to have a significant impact on the incidence or severity of BPD. Many strategies which have proven to be effective on paper have not shown similar outcomes when applied to clinical settings. There is continued need for

future meta-analyses and prospective randomized controlled studies designed to measure clinically meaningful outcomes, and an even greater need to design trials evaluating the safety, efficacy, and dosing of pharmacologic agents in this population. Also, future research should be focused on establishing better biomarkers predictive of BPD and associated longer-term chronic respiratory morbidity, developing stratification models to identify high-risk infants early on, and applying a multimodal approach when studying various pharmacologic interventions. Stem cell treatment and other such innovative strategies may be the beginning of a new era in the treatment of BPD. New ways of preventing or modulating BPD are on the horizon, and will hopefully lead to continued improvement of long-term outcome of prematurely born infants.⁸²

REFERENCES

1. Kair LR, Leonard DT, Anderson JM. Bronchopulmonary dysplasia. Pediatrics in review. 2012 Jun;33(6):255-64.
2. Walsh MC, Szeffler S, Davis J, Allen M, Van Marter L, Abman S, Blackmon L, Jobe A. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics. 2006 Mar;117(Supplement_1):S52-6.
3. Siffel C, Kistler KD, Lewis JF, Sarda SP. Global incidence of bronchopulmonary dysplasia among extremely preterm infants: a systematic literature review. The Journal of Maternal-Fetal & Neonatal Medicine. 2021 Jun 3;34(11):1721-31.
4. Van Marter LJ. Epidemiology of bronchopulmonary dysplasia. InSeminars in Fetal and Neonatal Medicine 2009 Dec 1 (Vol. 14, No. 6, pp. 358-366). WB Saunders.
5. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988 Oct;82(4):527-32.
6. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American journal of respiratory and critical care medicine. 2001 Jun 1;163(7):1723-9.
7. Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, Everette R, Peters N, Miller N, Muran G, Auten K. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. 2004 Nov;114(5):1305-11.
8. Isayama T, Lee SK, Yang J, Lee D, Daspal S, Dunn M, Shah PS, Canadian Neonatal Network, Canadian Neonatal Follow-Up Network Investigators. Revisiting the definition

of bronchopulmonary dysplasia: effect of changing panoply of respiratory support for preterm neonates. *JAMA pediatrics*. 2017 Mar 1;171(3):271-9.

9. Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, Ryan RM, Kallapur SG, Steinhorn RH, Konduri GG, Davis SD. Bronchopulmonary dysplasia: executive summary of a workshop. *The Journal of pediatrics*. 2018 Jun 1;197:300-8.
10. Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, Kirpalani H, Laughon MM, Poindexter BB, Duncan AF, Yoder BA. The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. *American journal of respiratory and critical care medicine*. 2019 Sep 15;200(6):751-9.
11. Old BP, New BP. What is Bronchopulmonary Dysplasia?.
12. Carraro S, Filippone M, Da Dalt L, Ferraro V, Maretti M, Bressan S, El Mazloum D, Baraldi E. Bronchopulmonary dysplasia: the earliest and perhaps the longest lasting obstructive lung disease in humans. *Early human development*. 2013 Oct 1;89:S3-5.
13. Davis JM, Auten RL. Maturation of the antioxidant system and the effects on preterm birth. *InSeminars in fetal and neonatal medicine* 2010 Aug 1 (Vol. 15, No. 4, pp. 191-195). WB Saunders.
14. Coalson JJ. Pathology of new bronchopulmonary dysplasia. *InSeminars in neonatology* 2003 Feb 1 (Vol. 8, No. 1, pp. 73-81). WB Saunders.
15. Jobe AH. The new bronchopulmonary dysplasia. *Current opinion in pediatrics*. 2011 Apr;23(2):167.
16. Coalson JJ. Pathology of new bronchopulmonary dysplasia. *InSeminars in neonatology* 2003 Feb 1 (Vol. 8, No. 1, pp. 73-81). WB Saunders.
17. Jobe AH. Mechanisms of lung injury and bronchopulmonary dysplasia. *American journal of perinatology*. 2016 Sep;33(11):1076-8.
18. Eriksson L, Haglund B, Odlind V, Altman M, Ewald U, Kieler H. Perinatal conditions related to growth restriction and inflammation are associated with an increased risk of bronchopulmonary dysplasia. *Acta Paediatrica*. 2015 Mar;104(3):259-63.
19. Merritt TA, Deming DD, Boynton BR. The 'new'bronchopulmonary dysplasia: challenges and commentary. *InSeminars in Fetal and Neonatal Medicine* 2009 Dec 1 (Vol. 14, No. 6, pp. 345-357). WB Saunders.
20. O'Reilly M, Sozo F, Harding R. Impact of preterm birth and bronchopulmonary dysplasia on the developing lung: long-term consequences for respiratory health. *Clinical and Experimental Pharmacology and Physiology*. 2013 Nov;40(11):765-73.
21. Bhandari V, Bizzarro MJ, Shetty A, Zhong X, Page GP, Zhang H, Ment LR, Gruen JR, Neonatal Genetics Study Group. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. *Pediatrics*. 2006 Jun;117(6):1901-6.22).
22. Parker RA, Lindstrom DP, Cotton RB. Evidence from twin study implies possible genetic susceptibility to bronchopulmonary dysplasia. *InSeminars in perinatology* 1996 Jun 1 (Vol. 20, No. 3, pp. 206-209). WB Saunders.
23. Dammann CE, Ramadurai SM, McCants DD, Pham LD, Nielsen HC. Androgen regulation of signaling pathways in late fetal mouse lung development. *Endocrinology*. 2000 Aug 1;141(8):2923-9.
24. Albertine KH, Jones GP, Starcher BC, Bohnsack JF, Davis PL, Cho SC, Carlton DP, Bland RD. Chronic lung injury in preterm lambs: disordered respiratory tract development. *American journal of respiratory and critical care medicine*. 1999 Mar 1;159(3):945-58.
25. Welty SE. Antioxidants and oxidations in bronchopulmonary dysplasia: there are no easy answers. *The Journal of pediatrics*. 2003 Dec 1;143(6):697-8.
26. Hannaford K, Todd DA, Jeffery H, John E, Blyth K, Gilbert GL. Role of Ureaplasmaurealyticum in lung disease of prematurity. *Archives of Disease in Childhood-Fetal and Neonatal Edition*. 1999 Nov 1;81(3):F162-7.
27. Lahra MM, Beeby PJ, Jeffery HE. Intrauterine inflammation, neonatal sepsis, and chronic lung disease: a 13-year hospital cohort study. *Pediatrics*. 2009 May;123(5):1314-9.
28. Saugstad OD. Bronchopulmonary dysplasia—oxidative stress and antioxidants. *InSeminars in Neonatology* 2003 Feb 1 (Vol. 8, No. 1, pp. 39-49). WB Saunders.
29. Lewis BA, Singer LT, Fulton S, Salvator A, Short EJ, Klein N, Baley J. Speech and language outcomes of children with bronchopulmonary dysplasia. *Journal of communication disorders*. 2002 Sep 1;35(5):393-406.
30. Halvorsen T, Skadberg BT, Eide GE, Røksund OD, Carlsen KH, Bakke P. Pulmonary outcome in adolescents of extreme preterm birth: a regional cohort study. *Acta Paediatrica*. 2004 Oct;93(10):1294-300.
31. Wong PM, Lees AN, Louw J, Lee FY, French N, Gain K, Murray CP, Wilson A, Chambers DC. Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia. *European Respiratory Journal*. 2008 Aug 1;32(2):321-8.

32. Principi N, Di Pietro GM, Esposito S. Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies. *Journal of translational medicine*. 2018 Dec;16(1):1-3.

33. Ralser E, Mueller W, Haberland C, Fink FM, Gutenberger KH, Strobl R, Kiechl-Kohlendorfer U. Rehospitalization in the first 2 years of life in children born preterm. *Acta Paediatrica*. 2012 Jan;101(1):e1-5.

34. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. *Pediatrics*. 1988 Aug;82(2):199-203.

35. Halvorsen T, Skadberg BT, Eide GE, Røksund O, Aksnes L, Øymar K. Characteristics of asthma and airway hyper-responsiveness after premature birth. *Pediatric allergy and immunology*. 2005 Sep;16(6):487-94.

36. Karila C, Saulnier JP, Elie C, Taupin P, Scheinmann P, Le Bourgeois M, Waernessytle S, de Blic J. Exercise alveolar hypoventilation in long-term survivors of bronchopulmonary dysplasia. *Revue des maladies respiratoires*. 2008 Mar 1;25(3):303-12.

37. Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. *Pediatrics*. 2008 Feb;121(2):317-25.

38. Kumar VH. Diagnostic approach to pulmonary hypertension in premature neonates. *Children*. 2017 Aug 24;4(9):75.

39. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Early CPAP versus surfactant in extremely preterm infants. *New England Journal of Medicine*. 2010 May 27;362(21):1970-9.

40. Thome UH, Ambalavanan N. Permissive hypercapnia to decrease lung injury in ventilated preterm neonates. In: *Seminars in fetal and neonatal medicine* 2009 Feb 1 (Vol. 14, No. 1, pp. 21-27). WB Saunders.

41. Miller JD, Carlo WA. Safety and effectiveness of permissive hypercapnia in the preterm infant. *Current opinion in pediatrics*. 2007 Apr 1;19(2):142-4.

42. Lemyre B, Laughon M, Bose C, Davis PG. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants. *Cochrane Database of Systematic Reviews*. 2016(12).

43. Cools F, Offringa M, Askie LM. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. *Cochrane Database of Systematic Reviews*. 2015(3).

44. Klingenbergs C, Wheeler KI, McCallion N, Morley CJ, Davis PG. Volume-targeted versus pressure limited ventilation in neonates. *Cochrane Database of Systematic Reviews*. 2017(10).

45. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. *New England Journal of Medicine*. 2003 Sep 4;349(10):959-67.

46. STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes. *Pediatrics*. 2000 Feb 1;105(2):295-310.

47. BOOST II United Kingdom, Australia, and New Zealand Collaborative Groups. Oxygen saturation and outcomes in preterm infants. *New England Journal of Medicine*. 2013 May 30;368(22):2094-104.

48. Principi N, Di Pietro GM, Esposito S. Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies. *Journal of translational medicine*. 2018 Dec;16(1):1-3.

49. Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. *Cochrane Database of Systematic Reviews*. 2012(11).

50. Brix N, Sellmer A, Jensen MS, Pedersen LV, Henriksen TB. Predictors for an unsuccessful INTubation-SURfactant-Extubation procedure: a cohort study. *BMC pediatrics*. 2014 Dec;14:1-8.

51. Vento G, Ventura ML, Pastorino R, van Kaam AH, Carnielli V, Cools F, Dani C, Mosca F, Polglase G, Tagliabue P, Boni L. Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trial. *The Lancet Respiratory Medicine*. 2021 Feb 1;9(2):159-66.

52. Rigo V, Lefebvre C, Broux I. Surfactant instillation in spontaneously breathing preterm infants: a systematic review and meta-analysis. *European journal of pediatrics*. 2016 Dec;175:1933-42.

53. Johnson JW, Mitzner W, Beck JC, London WT, Sly DL, Lee PA, Khouzami VA, Cavalieri RL. Long-term effects of betamethasone on fetal development. *American journal of obstetrics and gynecology*. 1981 Dec 15;141(8):1053-64.

54. Yoder Jr MC, Chua R, Tepper R. Effect of

dexamethasone on pulmonary inflammation and pulmonary function of ventilator-dependent infants with bronchopulmonary dysplasia. *American Review of Respiratory Disease*. 2012 Dec 17.

55. Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, Zupan-Simunek V, Coursol A, Beuchée A, Bolot P, Andrini P. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. *The Lancet*. 2016 Apr 30;387(10030):1827-36.

56. Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, Tsai CH, Lin HC. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. *American journal of respiratory and critical care medicine*. 2016 Jan 1;193(1):86-95.

57. Davis JM, Bhutani VK, Stefano JL, Fox WW, Spitzer AR. Changes in pulmonary mechanics following caffeine administration in infants with bronchopulmonary dysplasia. *Pediatric pulmonology*. 1989;6(1):49-52.

58. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W. Caffeine therapy for apnea of prematurity. *New England Journal of Medicine*. 2006 May 18;354(20):2112-21.

59. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W. Long-term effects of caffeine therapy for apnea of prematurity. *New England Journal of Medicine*. 2007 Nov 8;357(19):1893-902.

60. Lodha A, Seshia M, McMillan DD, Barrington K, Yang J, Lee SK, Shah PS, Canadian Neonatal Network. Association of early caffeine administration and neonatal outcomes in very preterm neonates. *JAMA pediatrics*. 2015 Jan 1;169(1):33-8.

61. Marconi E, Bettoli A, Ambrosio G, Perduca V, Vannacci A, Troiani S, Dani C, Mugelli A, Lucenteforte E. Efficacy and safety of pharmacological treatments for patent ductusarteriosus closure: a systematic review and network meta-analysis of clinical trials and observational studies. *Pharmacological research*. 2019 Oct 1;148:104418.

62. Clyman RI, Kaempf J, Liebowitz M, Erdeve O, Bulbul A, Håkansson S, Lindqvist J, Farooqi A, Katheria A, Sauberan J, Singh J. Prolonged tracheal intubation and the association between patent ductusarteriosus and bronchopulmonary dysplasia: a secondary analysis of the PDA-TOLERATE trial. *The Journal of pediatrics*. 2021 Feb 1;229:283-8.

63. Sankar MN, Bhombal S, Benitz WE. PDA: to treat or not to treat. *Congenital heart disease*. 2019 Jan;14(1):46-51.

64. Rush MG, Engelhardt B, Parker RA, Hazinski TA. Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. *The Journal of pediatrics*. 1990 Jul 1;117(1):112-8.

65. Stewart A, Brion LP. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. *Cochrane Database of Systematic Reviews*. 2011(9).

66. Engelhardt B, Blalock WA, DonLevy S, Rush M, Hazinski TA. Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic bronchopulmonary dysplasia. *The Journal of pediatrics*. 1989 Apr 1;114(4):619-24.

67. Ng G, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. *Cochrane Database of Systematic Reviews*. 2016(12).

68. Brundage KL, Mohsini KG, Froese AB, Fisher JT. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. *American Review of Respiratory Disease*. 2012 Dec 17.

69. Gadhia MM, Cutter GR, Abman SH, Kinsella JP. Effects of early inhaled nitric oxide therapy and vitamin A supplementation on the risk for bronchopulmonary dysplasia in premature newborns with respiratory failure. *The Journal of pediatrics*. 2014 Apr 1;164(4):744-8.

70. Ambalavanan N, Tyson JE, Kennedy KA, Hansen NI, Vohr BR, Wright LL, Carlo WA, National Institute of Child Health and Human Development Neonatal Research Network. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. *Pediatrics*. 2005 Mar;115(3):e249-54.

71. Uberos J, Miras-Baldo M, Jerez-Calero A, Narbona-López E. Effectiveness of vitamin A in the prevention of complications of prematurity. *Pediatrics & Neonatology*. 2014 Oct 1;55(5):358-62.

72. Davis JM, Richter SE, Biswas S, Rosenfeld WN, Parton L, Gewolb IH, Parad R, Carlo W, Couser RJ, Baumgart S, Atluru V. Long-term follow-up of premature infants treated with prophylactic, intratracheal recombinant human CuZn superoxide dismutase. *Journal of Perinatology*. 2000 Jun;20(4):213-6.

73. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W, North American Recombinant Human CuZnSOD Study Group. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. *Pediatrics*. 2003 Mar;111(3):469-76.

74. Ting JY, Roberts A, Sherlock R, Ojah C, Cieslak Z, Dunn M, Barrington K, Yoon EW, Shah PS, Canadian Neonatal Network Investigators. Duration of initial empirical antibiotic therapy and outcomes in very low birth weight infants. *Pediatrics*. 2019 Mar 1;143(3).

75. Viscardi RM, Terrin ML, Magder LS, Davis NL, Dulkerian SJ, Waites KB, Ambalavanan N, Kaufman DA, Donohue P, Tuttle DJ, Weitkamp JH. Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants. *Archives of Disease in Childhood-Fetal and Neonatal Edition*. 2020 Nov 1;105(6):615-22.

76. Pasha AB, Chen XQ, Zhou GP. Bronchopulmonary dysplasia: Pathogenesis and treatment. Experimental and the therapeutic medicine. 2018 Dec 1;16(6):4315-21.

77. Sinclair K, Yerkovich ST, Chambers DC. Mesenchymal stem cells and the lung. *Respirology*. 2013 Apr;18(3):397-411.

78. Willis GR, Fernandez-Gonzalez A, Anastas J, Vitali SH, Liu X, Ericsson M, Kwong A, Mitsialis SA, Kourembanas S. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. *American journal of respiratory and critical care medicine*. 2018 Jan 1;197(1):104-16.

79. Hellstrom A, Engstrom E, Hard AL, Albertsson-Wikland K, Carlsson B, Niklasson A, Lofqvist C, Svensson E, Holm S, Ewald U, Holmstrom G. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. *Pediatrics*. 2003 Nov;112(5):1016-20.

80. Levine CR, Gewolb IH, Allen K, Welch RW, Melby JM, Pollack S, Shaffer T, Pilon AL, Davis JM. Safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. *Pediatric research*. 2005 Jul;58(1):15-21.

81. Álvarez-Fuente M, Arruza L, Muro M, Zozaya C, Avila A, López-Ortego P, González-Armengod C, Torrent A, Gavilán JL, Del Cerro MJ. The economic impact of prematurity and bronchopulmonary dysplasia. *European journal of pediatrics*. 2017 Dec;176:1587-93.

82. Bonadies L, Zaramella P, Porzionato A, Perilongo G, Muraca M, Baraldi E. Present and future of bronchopulmonary dysplasia. *Journal of clinical medicine*. 2020 May 20;9(5):1539.

Red Flower Publication Pvt. Ltd.

CAPTURE YOUR MARKET

For advertising in this journal

Please contact:

International print and online display advertising sales

Advertisement Manager

Phone: 91-11-79695648, Cell: +91-9821671871

E-mail: info@rfppl.co.in

Recruitment and Classified Advertising

Advertisement Manager

Phone: 91-11-79695648, Cell: +91-9821671871

E-mail: info@rfppl.co.in

Pediatric Education and Research

Library Recommendation Form

If you would like to recommend this journal to your library, simply complete the form given below and return it to us. Please type or print the information clearly. We will forward a sample copy to your library, along with this recommendation card.

Please send a sample copy to:

Name of Librarian

Name of Library

Address of Library

Recommended by:

Your Name/ Title

Department

Address

Dear Librarian,

I would like to recommend that your library subscribe to the Pediatric Education and Research. I believe the major future uses of the journal for your library would provide:

1. Useful information for members of my specialty.
2. An excellent research aid.
3. An invaluable student resource.

I have a personal subscription and understand and appreciate the value an institutional subscription would mean to our staff.

Should the journal you're reading right now be a part of your University or institution's library? To have a free sample sent to your librarian, simply fill out and mail this today!

Stock Manager

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091(India)

Phone: 91-11-79695648

Cell: +91-9821671871

E-mail: info@rfppl.co.in

Multiple Co-Infections in a Child with Beta Thalassemia Major: A Rare Case Report

Mumtaz Sharif¹, Amit Saxena², Vinaykumar P Hedaginal³, Divyani Dhole⁴

How to cite this article:

Mumtaz Sharif, Amit Saxena, Vinaykumar P Hedaginal, *et al.*/Multiple Co-Infections in a Child with Beta Thalassemia Major: A Rare Case Report/Pediatr Edu Res. 2023;11(2): 71-73.

Abstract

Beta Thalassemia is a hereditary blood disorder characterized by defect in synthesis of beta chains of haemoglobin requiring regular blood transfusion and chelation therapy. Blood transfusions can lead to many complications of which transfusion transmitted infections like HCV, HBsAg, HIV etc are possible. Iron overload is another complication of repeated blood transfusion which further predisposes them to many infections like Mycobacterium Tuberculosis. Hemophagocytic Lymphohistiocytosis (HLH) is one of the rare complication where there is abnormal activation of immune system which results in cytokine storm. Here we present a case of transfusion dependent thalassemia patient, who developed HCV and Pulmonary Kochs complicated with HLH all at the same time and was managed successfully.

Keywords: Thalassemia; HCV; Tuberculosis; HLH.

INTRODUCTION

β-thalassemia major is an autosomal recessive disorder requiring regular blood transfusion and chelation therapy.¹ Infection is one of the cause of morbidity and mortality in thalassemia patient. The underlying mechanism of increased susceptibility to infections is specific to unscreened blood transfusion, iron overload, splenectomy, chelation therapy.

The implementation of viral NAT testing has significantly reduced the risk of viral transmission through blood products during the window period.^{2,3} However, these infections still can occur in settings of developing countries where blood is

poorly screened with old techniques.

Regular transfusions leads to iron overload in various organs leading to organ dysfunction. It also increases the predisposition to infections including TB. Adequate chelation therapy is required to prevent and reduce susceptibility to infections.^{4,5}

Hemophagocytic lymphohistiocytosis (HLH) is a rare, potentially fatal condition in which abnormal activation of the immune system results in hemophagocytosis, inflammation and tissue damage. HLH can be either primary (familial) or secondary (sporadic, acquired). Secondary HLH can occur secondary to many infections, including Mycobacterium tuberculosis (MTB).

These illnesses have high morbidity and mortality individually which can increase significantly when combined together. Early diagnosis and timely intervention is the key to managing such a child.

CASE REPORT

13 year old male child, a known case of Transfusion Dependent B Thalassemia was

Author's Affiliation: ^{1,2}Professor, ¹Junior Resident, ²Senior Resident, Department of Pediatrics, DY Patil (Deemed to be University), Navi Mumbai 400706, Maharashtra, India.

Corresponding Author: Vinaykumar P Hedaginal, Junior Resident, Department of Pediatrics, DY Patil (Deemed to be University), Navi Mumbai 400706, Maharashtra, India.

E-mail: mumtaz23.75@gmail.com.

Received on: 02.03.2023

Accepted on: 12.04.2023

following up regularly for blood transfusion and chelation therapy at our centre. Child was monitored regularly for transfusion transmitted infections as per protocol and was negative for HIV, HCV, HBSAG, etc. During the pandemic of covid, the patient shifted to his village and took transfusions there. Chelation therapy was discontinued due to unavailability of the drugs for 9 months.

The child presented to us with complaints of high grade fever without focus since 3 days. On examination, the child was sick looking and had tachycardia. He had generalized lymphadenopathy with stunting and wasting on anthropometric measurements. The abdomen was distended with massive hepatomegaly (span 22cm). The child was splenectomised 5 years back for hypersplenism. His CBC showed Hb of 11 gm/dl, TLC-13600 cells/cumm, Platelet - 3 lakhs, ESR was elevated (85 mm at end of 1 hr). Ferritin was 69750ng/ml. Electrolytes were normal. Serological tests for Malaria, Dengue and Typhoid were negative. Covid-19 RTPCR was negative. Blood culture was negative, urine was sterile. On screening, he was detected to have developed anti HCV antibodies.

Patient was started on IV Ceftriaxone. Even after 48 hours of antibiotics, patient had high grade fever & persistent vomiting and developed hypotension, so antibiotics were stepped up to Meropenem and Vancomycin. Patient was shifted to PICU. Serum electrolytes showed severe hyponatremia (Na⁺ - 121) and hypokalemia (K⁺ - 3.2) and correction fluids were started. Patient developed ascites, episodes of desaturation and hypotension persisted, so oxygen and inotropic support was given. X ray chest showed findings suggestive of Koch's. Hence was further worked up by doing HRCT chest which showed enlarged pre and para tracheal, sub carinal and multiple mediastinal lymphnodes with calcification which were consistent with Kochs, however however MT (MantouxTest) and Gene expert were negative. FNAC of lymph nodes was done which was inconclusive due to scanty cellularity. AKT was started as per RNTCP DOTS. Repeat CBC showed pancytopenia along with persistent fever, so HLH work up was done. Serum triglycerides, soluble cd25 and fibrinogen were normal. On strong suspicion Bone Marrow aspiration and Biopsy was done which was suggestive of hemophagocytosis. Patient was started on dexamethasone @10mg/m² as per HLH protocol

The child showed gradual improvement with reduction of fever, inotropic support and oxygen requirement and normalization of electrolytes.

Child was started on oral feeds. Chelation therapy was restarted and serum Ferritin was repeated, which came down to 16,072 ng/ml. As patient was hemodynamically stable, he was shifted to oral dexamethasone and referred to gastroenterologist for further management of HCV and advised to



Fig 1: Photograph showing the massive Liver on the right side of the body and splenectomy scar on left side of the body.

complete the AKT treatment.

DISCUSSION

Beta Thalassemia patients receive regular blood transfusion which results in Iron over load. Iron and its binding proteins has immunoregulatory properties. Iron excess may derange the immune balance in favour of the growth of infectious organisms. Other factors which increase susceptibility to infections include multiple transfusions increasing risk of Transfusion transmitted infections and splenectomy.⁶ Our patient was on regular blood transfusion with irregular chelation with massive hepatomegaly and was splenectomised, which resulted in immuno compromised state.

Tuberculosis is an opportunistic infection having non-specific nature of symptoms making diagnosis difficult. Immunocompromised state increases the risk of Tuberculosis⁷. Combination of clinical, radiological, lab findings and epidemiological evidence of TB exposure allows for an accurate diagnosis. A study by Sriwijitali et al showed a common pathway via glutathione which imply the increased risk for tuberculosis among the patients

with thalassemia.⁸

HLH is characterised by persistent fever with hepatomegaly, splenomegaly, lymphadenopathy, cytopenia, hypertriglyceridemia, hypofibrinogenemia and bleeding.⁹ There is stimulation of immune responses which results in macrophage infiltration and cytokinestorm.¹⁰ The excessive activated macrophages engulf host blood cells (hemophagocytosis) which can be seen in biopsies from lymph nodes, bone marrow, liver and spleen. Secondary HLH can be triggered by infections, most commonly viral infections like EBV, CMV, HCV, HBV, Dengue, etc and also with fungal, parasitic and bacterial infections, including Mycobacterium tuberculosis (TB). Timely diagnosis and initiation of treatment is an important factor in prognostication. Study conducted by Zhang et al showed around 3.5% prevalence of HLH in Tuberculosis patient.¹¹

Due to covid pandemic and unavailability of drugs, our patient was not on regular chelation therapy and received unscreened blood transfusion and developed HCV infection. Most patients of hepatitis C have non-specific symptoms during acute phase. The severity of liver fibrosis correlates to liver iron over load in chronic hepatitis C. Manifestations in patients with decompensated liver disease include ankle oedema, abdominal distension (ascites), hematemesis or melena (variceal bleeding) with abnormal liver function tests and mental status changes (hepatic encephalopathy).¹² Study conducted by Thalassaemia Control Unit, Imambara Sadar Hospital showed 25% prevalence of HCV in thalassemia patient.¹³

Even though complications of Hep C infection, Tb and HLH can occur in a thalassemia patient, all these occurring together complicating a case of thalassemia is rarely seen. Early diagnosis and recognition of complications helped us in managing the case successfully.

CONCLUSION

HCV infection can occur in thalassemia due to inadequate screening technique or window period. TB is an endemic illness in India, more common in immunocompromised conditions such as splenectomised thalassemia child. In a child with persistent fever with pancytopenia, diagnosis of HLH should be considered early as prompt diagnosis and treatment can be life saving.

REFERENCES

1. Cao A, Galanello R. Beta-thalassemia. Genet

2. Dodd RY, Notari EP, Stramer SL: Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. *Transfusion*. 2002; 42 (8): 975-979. 10.1046/j.1537-2995.2002.00174.x.
3. Busch GM: Closing the window on viral transmission by blood transfusion. *Blood Safety in the new millennium*. Edited by: SL S. 2001, Bethesda, MD, American Association of Blood Banks, 33-54.
4. Cronje L, Bornman L. Iron overload and tuberculosis: a case for iron chelation therapy. *Int J Tuberc Lung Dis*. 2005 Jan;9(1):2-9. PMID: 15675543.
5. Olivieri NF, Brittenham GM. Iron chelating therapy and the treatment of thalassemia. *Blood* 89: 739-761, 1997.
6. Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. *Med Sci Monit*. 2003 Jan;9(1):RA19-22. PMID: 12552254.
7. Marais BJ, Schaaf HS. Tuberculosis in children. *Cold Spring Harb Perspect Med*. 2014;4(9):a017855. Published 2014 Jul 18. doi:10.1101/cshperspect.a017855.
8. Sriwijitalai W, Wiwanitkit V. Tuberculosis in patients with underlying thalassemia: a consideration of common antioxidative pathway – an expressional analysis. *Egypt J Chest Dis Tuberc* 2021;70:38-9.
9. The Pediatric Infectious Disease Journal: March 2019 - Volume 38 - Issue 3 - p e54-e56 doi: 10.1097/INF.0000000000002248.
10. Ishii E. Hemophagocytic Lymphohistiocytosis in Children: Pathogenesis and Treatment. *Front Pediatr*. 2016;4:47. Published 2016 May 13. doi:10.3389/fped.2016.00047.
11. Zhang Y, Liang G, Qin H, Li Y, Zeng X. Tuberculosis-associated hemophagocytic lymphohistiocytosis with initial presentation of fever of unknown origin in a general hospital: An analysis of 8 clinical cases. *Medicine (Baltimore)*. 2017;96(16):e6575. doi:10.1097/MD.0000000000006575.
12. Elalfy MS, Esmat G, Matter RM, et al. Liver fibrosis in young Egyptian beta-thalassemia major patients: Relation to hepatitis C virus and compliance with chelation. *Annals of Hepatology*. 2013;12:54-61.
13. Asian J Transfus Sci. 2018 Jul-Dec; 12(2): 112-116. doi: 10.4103/ajts.AJTS_73_17.

REDKART.NET

(A product of RF Library Services (P) Limited)
(Publications available for purchase: Journals, Books, Articles and Single issues)
(Date range: 1967 to till date)

The Red Kart is an e-commerce and is a product of RF Library Services (P) Ltd. It covers a broad range of journals, Books, Articles, Single issues (print & Online-PDF) in English and Hindi languages. All these publications are in stock for immediate shipping and online access in case of online.

Benefits of shopping online are better than conventional way of buying.

1. Convenience.
2. Better prices.
3. More variety.
4. Fewer expenses.
5. No crowds.
6. Less compulsive shopping.
7. Buying old or unused items at lower prices.
8. Discreet purchases are easier.

URL: www.redkart.net

SUBSCRIPTION FORM

I want to renew/subscribe international class journal “**Pediatric Education and Research**” of Red Flower Publication Pvt. Ltd.

Subscription Rates:

- Institutional: **8500 / USD 664.06**

Name and complete address (in capitals): _____

Payment detail:

Online payment link: <http://rfppl.co.in/payment.php?mid=15>

Cheque/DD: Please send the US dollar check from outside India and INR check from India made payable to ‘Red Flower Publication Private Limited’. Drawn on Delhi branch.

Wire transfer/NEFT/RTGS:

Complete Bank Account No. 604320110000467

Beneficiary Name: Red Flower Publication Pvt. Ltd.

Bank & Branch Name: Bank of India; Mayur Vihar

MICR Code: 110013045

Branch Code: 6043

IFSC Code: BKID0006043 (used for RTGS and NEFT transactions)

Swift Code: BKIDINBBDS

Term and condition for supply of journals

1. Advance payment required by Demand Draft payable to **Red Flower Publication Pvt. Ltd.** payable at **Delhi**.
2. Cancellation not allowed except for duplicate payment.
3. Agents allowed 12.5% discount.
4. Claim must be made within six months from issue date.

Mail all orders to

Subscription and Marketing Manager

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091(India).

Phone: 91-11-79695648

Cell: +91-9821671871

E-mail: sales@rfppl.co.in

Instructions to Authors

Submission to the journal must comply with the Guidelines for Authors. Non-compliant submission will be returned to the author for correction.

To access the online submission system and for the most up-to-date version of the Guide for Authors please visit:

<http://www.rfppl.co.in>

Technical problems or general questions on publishing with PER are supported by Red Flower Publication Pvt. Ltd.'s Author Support team (http://rfppl.co.in/article_submission_system.php?mid=5#)

Alternatively, please contact the Journal's Editorial Office for further assistance.

Editorial Manager

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091(India).

Mobile: 9821671871, Phone: 91-11-79695648

E-mail: author@rfppl.co.in

Learning Disability in a Case of Primary Ciliary Dyskinesia: A Case Report

Jagdish Taur¹, Praveen Unki², Santosh Kondekar³, Suraksha Sharma⁴,
Qudsia Ansari⁵, Surbhi Rath⁶

How to cite this article:

Jagdish Taur, Praveen Unki, Santosh Kondekar *et al.*/Learning Disability in a Case of Primary Ciliary Dyskinesia: A Case Report/Pediatr Edu Res. 2023;11(2): 77-80.

Abstract

Primary ciliary dyskinesia (PCD) is a genetic disorder of cilia structure, function and biogenesis leading to chronic infections of the respiratory tract, due to congenital impairment of mucociliary clearance. Mutation in genes coding components of cilia can result in primary ciliary dyskinesia.

Learning disabilities are the disorders that affect the acquisition, retention, comprehension or the application of verbal and or nonverbal information.

Our patient presented with recurrent respiratory tract infection requiring nebulization with antibiotics treatment on Out patient department basis. Child's Radiological investigation and Genetic study were planned and done which later confirmed the diagnosis. Child also had poor Scholastic performance along with behavioral issues for which detailed psychiatric evaluation was done which was suggestive of border line intellectual deficit with learning disability and Attention Deficit Hyperactive Disorder (ADHD) for which child was started on treatment along with behavioral therapy.

Keywords: Primary ciliary Dyskinesia; Learning Disability; Genetic Study.

INTRODUCTION

Primary ciliary dyskinesia (PCD) is usually an

Author's Affiliation: ^{1,4}Junior Resident, ³Associate Professor, ^{2,5}Assistant Professor, ⁶Professor & HOD, Department of Pediatrics, Topiwala National Medical College & BYL Nair Charitable Hospital, Mumbai 400008, Maharashtra, India.

Corresponding Author: Praveen Unki, Assistant Professor, Department of Pediatrics, Topiwala National Medical College & BYL Nair Charitable hospital, Mumbai 400008, Maharashtra, India.

E-mail: praveenu3@gmail.com

Received on: 03.04.2023

Accepted on: 17.04.2023

heterogeneous genetic condition characterized by structure, function and biogenesis leading to chronic infections of the respiratory tract.¹ The defect can be in any proteins needed for making functional cilia, different clinical manifestation can be seen as per defect. Repeated infection can cause damage to the lungs and airways leading to development of bronchiectasis.

In some cases, as primary cilia are important in embryonic development of the central nervous system such as neuronal progenitor cell proliferation and generation of neurons in various parts of brain as well as migration.^{2,4} Also, some people affected with PCD can have situs inversus in which the position of internal organs in the body are reversed from normal.⁵

Learning disabilities refer to group of disorders that affect the acquisition, retention, organization, comprehension or the application of verbal and or nonverbal information.⁶

Learning disability is condition which affect the information sent, received & processed by brain. They are of various type and are due to problem in brain development and cause difficulty in reading, writing, understanding one or more concepts and or subjects.⁷

CASE

A 12-year-old male child with a history of recurrent respiratory tract infection with borderline intellectual deficit with difficulty in school performance. Child had significant birth history with pneumonia on day of life 3 requiring mechanical ventilation and prolonged NICU stay. Later on, child had 4 admissions requiring oxygen therapy and intravenous medications for respiratory tract infections with recurrent episodes of cough, cold requiring treatment on out patient department (OPD) basis. There is a history of delay in achieving milestones for the child along with hyper activity and learning disability. Currently child has poor academic performance suggestive of intellectual deficit.

Radiological investigations suggestive of situs in versus totalis with HRCT suggestive of mucus secretion within segmental bronchi and mild bronchiectasis of left middle lobe and posterobasal

segment of left lung lobe forming consolidation likely secondary to mucoid impaction. BERA suggestive of moderate loss of hearing at high frequency. Considering child's presentation and investigation possibility of PCD suspected. Genetic study for PCD was sent and child was confirmed to have PCD With mutation in gene CCDC103/gene with pathogenic variant C461A>C.

Child had difficulty in concentrating, aggressive behavior which subsided after initiation of treatment. Along with difficulty in learning mathematics and science leading to poor scholastic performance, detailed evaluation of the child was done and was started on behavioral therapy for learning disability and ADHD.

DISCUSSION

Primary ciliary dyskinesia is a recessive genetic disease with more than 30 different genetic mutations that affect ciliary development have been identified.⁸ Males and females are equally affected. Typically, first symptoms occur at a very early age. Newborns with PCD often suffer from respiratory distress and require oxygen therapy for multiple days.⁹ As the child gets older, they have frequent respiratory tract infections.¹⁰ Detailed history and clinical examination along with imaging test are helpful for diagnosing PCD but most helpful being the genetic testing.

Treatment for PCD usually focuses on improving lung function and limiting disease progression.




Fig. 1: Chest X ray suggestive of Situs inversus Totalis.

Dyskinesia: A Case Report

Antibiotics can be used for lung or sinus infections.¹¹ Airway clearance methods including coughing and breathing techniques along with chest physical therapy can help to loosen the mucus from the lungs.¹²

PCD may lead to severe lung disease requiring oxygen treatment or breathing assist devices during strenuous activities, and if lungs are severely affected can require lung transplantation.¹³⁻¹⁵

The etiologies of Learning disorders can be influenced by hereditary and or environmental factors and are not precipitated by deficit in sensorimotor functioning. They are nearly twice common in the children with chronic illness as compared to healthy children. Risk factors include family history of learning disorder, poverty, prematurity and other neuro developmental disorders.¹⁶ Most common being Dyslexia. They often coexist with disorders like oppositional defiant disorder, attention deficit hyperactive disorder, anxiety and obsessive compulsive disorder.¹⁷

Evaluation of learning disorders done by first excluding the organic and functional differential diagnosis. Once the other differentials are ruled out diagnostic guidelines set out by the Diagnostic and Statistical Manual of Mental Disorders (DSM) along with relevant history of patient taken and wide varieties of test.

The most common treatment for learning disability is special education, detailed diagnostic evaluation assessing the child's academic and intellectual potential with basic approach is to teach learning skill by building on child's abilities and strength while correcting and compensating for disabilities. Multidisciplinary approach by educators, physician, speech therapist, psychologists, special services helps in the Most cases. Also it is important to monitor developmental progression, child's scholastic performance and school behavior. Prognosis of the it will depend on the severity of the learning disabilities and subsequent intervention and compliance to therapy.

CONCLUSION

The clinical exome for PCD group helped in confirming the clinical diagnosis and in providing better understanding of relationship between gene mutations and diagnostic phenotype. Irrespective of underlying genetic issue developmental delay, behavioral issues and learning disability has to be addressed. The child with PCD with proper management and life style modifications can have

better life style with less complications.

The PCD can affect the central nervous system by various ways and affect the proper development leading to learning disability in the affected individual. Early intervention and compliance to therapy leads to better outcomes in cases of learning disabilities.

REFERENCES

1. Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. *Eur Respir J* 1997; 10:2376-2379 [PubMed] [Google Scholar].
2. Valente EM, Rosti RO, Gibbs E, Gleeson JG. Primary cilia in neurodevelopmental disorders. *Nat Rev Neurol.* 2014 Jan;10(1):27-36. doi: 10.1038/nrneurol.2013.247. Epub 2013 Dec 3. PMID: 24296655; PMCID: PMC3989897.
3. Higginbotham H, et al. ARL13B in primary cilia regulates the migration and placement of interneurons in the developing cerebral cortex. *Dev. Cell.* 2012;23:925-938. [PMC free article] [PubMed] [Google Scholar].
4. Cantagrel V, et al. Mutations in the cilia gene ARL13B lead to the classical form of Joubert syndrome. *Am. J. Hum. Genet.* 2008;83:170-179. [PMC free article] [PubMed] [Google Scholar].
5. Basu B, Brueckner M. Cilia multifunctional organelles at the center of vertebrate left-right asymmetry. *Curr Top Dev Biol.* 2008;85:151-174. [PubMed] [Google Scholar] [Ref list].
6. Al-Mahrezi A, Al-Futaisi A, Al-Mamari W, Learning Disabilities: Opportunities and challenges in Oman. Sultan Qaboos University medical journal. 2016 May; [PubMed PMID: 27226902].
7. Ministry of Social Justice and Empowerment. Notification, 2018, Gazette of India (Extra-Ordinary) Department of Department of Empowerment of Persons with Disabilities (Divyangjan) 2018. Jan 4, [Last accessed on 2018 Mar 26]. Available from: <https://groups.google.com/d/topic/wethepwd/XuRiT0VdWsg>.
8. Zariwala MA, Knowles MR, Leigh MW. Primary Ciliary Dyskinesia. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. Gene Reviews(R); Seattle (WA): 1993. (updated Sept 2015) [Google Scholar] [Ref list].
9. Meeks M, Bush A. Primary ciliary dyskinesia (PCD). *Pediatr Pulmonol* 2000; 29:307-316 [PubMed] [Google Scholar].
10. Bush A, Chodhari R, Collins N, Copeland

Dyskinesia: A Case Report

F, Hall P, Harcourt J, et al. Primary ciliary dyskinesia: current state of the art. *Arch Dis Child* 2007; 92:1136-1140 [PMC free article] [PubMed] [Google Scholar] [Ref list].

11. King PT, Holmes PW. Use of antibiotics in bronchiectasis. *Rev Recent Clin Trials*. 2012;7:24-30. [PubMed] [Google Scholar].

12. Bradley J, Moran F, Greenstone M. Physical training for bronchiectasis. *Cochrane Database Syst Rev* (2002) 3: CD002166. doi:10.1002/14651858.CD002166PubMed Abstract | CrossRef Full Text | Google Scholar.

13. Gokdemir Y, Karadag-Saygi E, Erdem E, Bayindir O, Ersu R, Karadag B, et al. Comparison of conventional pulmonary rehabilitation and high-frequency chest wall oscillation in primary ciliary dyskinesia. *Pediatr Pulmonol* (2014) 49:611-6. doi:10.1002/ppul.22861 PubMed Abstract | CrossRef Full Text |.

14. Deuse T, Reitz BA. Heart-lung transplantation in situ inversus totalis. *Ann Thorac Surg* (2009) 88:1002-3. doi:10.1016/j.athoracsur.2009.01.060 PubMed Abstract | CrossRef Full Text | Google Scholar.

15. Shapiro AJ, Zariwala MA, Ferkol T, Davis SD, Sagel SD, Dell SD, et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. *Pediatr Pulmonol* (2016) 51:115-32. doi: 10.1002/ppul.23304.

16. Snowling MJ, Gallagher A, Frith U. Family risk of dyslexia is continuous: individual differences in the precursors of reading skill. *Child development*. 2003 Mar-Apr [PubMed PMID: 12705560].

17. Kohli A, Sharma S, Padhy SK. Specific Learning Disabilities: Issues that Remain Unanswered. *Indian journal of psychological medicine*. 2018 Sep-Oct; [PubMed PMID: 30275613].



REDKART.NET

(A product of RF Library Services (P) Limited)

(Publications available for purchase: Journals, Books, Articles and Single issues)

(Date range: 1967 to till date)

The Red Kart is an e-commerce and is a product of RF Library Services (P) Ltd. It covers a broad range of journals, Books, Articles, Single issues (print & Online-PDF) in English and Hindi languages. All these publications are in stock for immediate shipping and online access in case of online.

Benefits of shopping online are better than conventional way of buying.

1. Convenience.
2. Better prices.
3. More variety.
4. Fewer expenses.
5. No crowds.
6. Less compulsive shopping.
7. Buying old or unused items at lower prices.
8. Discreet purchases are easier.

URL: www.redkart.net

Guidelines for Authors

Manuscripts must be prepared in accordance with "Uniform requirements for Manuscripts submitted to Biomedical Journal" developed by international committee of medical Journal Editors

Types of Manuscripts and Limits

Original articles: Up to 3000 words excluding references and abstract and up to 10 references.

Review articles: Up to 2500 words excluding references and abstract and up to 10 references.

Case reports: Up to 1000 words excluding references and abstract and up to 10 references.

Online Submission of the Manuscripts

Articles can also be submitted online from http://rfppl.co.in/customer_index.php.

I) First Page File: Prepare the title page, covering letter, acknowledgement, etc. using a word processor program. All information which can reveal your identity should be here. use text/rtf/doc/PDF files. Do not zip the files.

2) Article file: The main text of the article, beginning from Abstract till References (including tables) should be in this file. Do not include any information (such as acknowledgement, your name in page headers, etc.) in this file. Use text/rtf/doc/PDF files. Do not zip the files. Limit the file size to 400 Kb. Do not incorporate images in the file. If file size is large, graphs can be submitted as images separately without incorporating them in the article file to reduce the size of the file.

3) Images: Submit good quality color images. Each image should be less than 100 Kb in size. Size of the image can be reduced by decreasing the actual height and width of the images (keep up to 400 pixels or 3 inches). All image formats (jpeg, tiff, gif, bmp, png, eps etc.) are acceptable; jpeg is most suitable.

Legends: Legends for the Fig.s/images should be included at the end of the article file.

If the manuscript is submitted online, the contributors' form and copyright transfer form has to be submitted in original with the signatures of all the contributors within two weeks from submission. Hard copies of the images (3 sets), for articles submitted online, should be sent to the journal office at the time of submission of a revised manuscript. Editorial office: Red Flower Publication Pvt. Ltd., 48/41-42, DSIDC, Pocket-II, Mayur Vihar Phase-I, Delhi - 110 091, India, Phone: 91-11-79695648, Cell: +91-9821671871. E-mail: author@rfppl.co.in. Submission page: http://rfppl.co.in/article_submission_system.php?mid=5.

Preparation of the Manuscript

The text of observational and experimental articles should be divided into sections with the headings: Introduction, Methods, Results, Discussion, References, Tables, Fig.s, Fig. legends, and Acknowledgment. Do not make subheadings in these sections.

Title Page

The title page should carry

- 1) Type of manuscript (e.g. Original article, Review article, Case Report)
- 2) The title of the article should be concise and informative;
- 3) Running title or short title not more than 50 characters;
- 4) The name by which each contributor is known (Last name, First name and initials of middle name), with his or her highest academic degree(s) and institutional affiliation;
- 5) The name of the department(s) and institution(s) to which the work should be attributed;
- 6) The name, address, phone numbers, facsimile numbers and e-mail address of the contributor responsible for correspondence about the manuscript; should be mentioned.
- 7) The total number of pages, total number of photographs and word counts separately for abstract and for the text (excluding the references and abstract);
- 8) Source(s) of support in the form of grants, equipment, drugs, or all of these;
- 9) Acknowledgement, if any; and
- 10) If the manuscript was presented as part at a meeting, the organization, place, and exact date on which it was read.

Abstract Page

The second page should carry the full title of the manuscript and an abstract (of no more than 150 words for case reports, brief reports and 250 words for original articles). The abstract should be structured and state the Context (Background), Aims, Settings and Design, Methods and Materials, Statistical analysis used, Results and Conclusions. Below the abstract should provide 3 to 10 keywords.

Introduction

State the background of the study and purpose of the study and summarize the rationale for the study or observation.

Methods

The methods section should include only information that was available at the time the plan or protocol for the study was written such as study approach, design, type of sample, sample size, sampling technique, setting of the study, description of data collection tools and methods; all information obtained during the conduct of the study belongs in the Results section.

Reports of randomized clinical trials should be based on the CONSORT Statement (<http://www.consort-statement.org>). When reporting experiments on human subjects, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 2000 (available at http://www.wma.net/e/policy/17-c_e.html).

Results

Present your results in logical sequence in the text, tables, and illustrations, giving the main or most important findings first. Do not repeat in the text all the data in the tables or illustrations; emphasize or summarize only important observations. Extra or supplementary materials and technical details can be placed in an appendix where it will be accessible but will not interrupt the flow of the text; alternatively, it can be published only in the electronic version of the journal.

Discussion

Include summary of key findings (primary outcome measures, secondary outcome measures, results as they relate to a prior hypothesis); Strengths and limitations of the study (study question, study design, data collection, analysis and interpretation); Interpretation and implications in the context of the totality of evidence (is there a systematic review to refer to, if not, could one be reasonably done here and now?; What this study adds to the available evidence, effects on patient care and health policy, possible mechanisms)? Controversies raised by this study; and Future research directions (for this particular research collaboration, underlying mechanisms, clinical

research). Do not repeat in detail data or other material given in the Introduction or the Results section.

References

List references in alphabetical order. Each listed reference should be cited in text (not in alphabetic order), and each text citation should be listed in the References section. Identify references in text, tables, and legends by Arabic numerals in square bracket (e.g. [10]). Please refer to ICMJE Guidelines (http://www.nlm.nih.gov/bsd/uniform_requirements.html) for more examples.

Standard journal article

[1] Flink H, Tegelberg Å, Thörn M, Lagerlöf F. Effect of oral iron supplementation on unstimulated salivary flow rate: A randomized, double-blind, placebo-controlled trial. *J Oral Pathol Med* 2006; 35: 540-7.

[2] Twetman S, Axelsson S, Dahlgren H, Holm AK, Kälestål C, Lagerlöf F, et al. Caries-preventive effect of fluoride toothpaste: A systematic review. *Acta Odontol Scand* 2003; 61: 347-55.

Article in supplement or special issue

[3] Fleischer W, Reimer K. Povidone-iodine antisepsis. State of the art. *Dermatology* 1997; 195 Suppl 2: 3-9.

Corporate (collective) author

[4] American Academy of Periodontology. Sonic and ultrasonic scalers in periodontics. *J Periodontol* 2000; 71: 1792-801.

Unpublished article

[5] Garoushi S, Lassila LV, Tezvergil A, Vallittu PK. Static and fatigue compression test for particulate filler composite resin with fiber-reinforced composite substructure. *Dent Mater* 2006.

Personal author(s)

[6] Hosmer D, Lemeshow S. *Applied logistic regression*, 2nd edn. New York: Wiley-Interscience; 2000.

Chapter in book

[7] Nauntofte B, Tenovuo J, Lagerlöf F. Secretion and composition of saliva. In: Fejerskov O,

Kidd EAM, editors. *Dental caries: The disease and its clinical management*. Oxford: Blackwell Munksgaard; 2003. pp 7-27.

No author given

[8] World Health Organization. *Oral health surveys - basic methods*, 4th edn. Geneva: World Health Organization; 1997.

Reference from electronic media

[9] National Statistics Online—Trends in suicide by method in England and Wales, 1979–2001. www.statistics.gov.uk/downloads/theme_health/HSQ20.pdf (accessed Jan 24, 2005): 7-18. Only verified references against the original documents should be cited. Authors are responsible for the accuracy and completeness of their references and for correct text citation. The number of reference should be kept limited to 20 in case of major communications and 10 for short communications.

More information about other reference types is available at www.nlm.nih.gov/bsd/uniform_requirements.html, but observes some minor deviations (no full stop after journal title, no issue or date after volume, etc.).

Tables

Tables should be self-explanatory and should not duplicate textual material.

Tables with more than 10 columns and 25 rows are not acceptable.

Table numbers should be in Arabic numerals, consecutively in the order of their first citation in the text and supply a brief title for each.

Explain in footnotes all non-standard abbreviations that are used in each table.

For footnotes use the following symbols, in this sequence: *, ¶, †, ‡.

Illustrations (Fig.s)

Graphics files are welcome if supplied as Tiff, EPS, or PowerPoint files of minimum 1200x1600 pixel size. The minimum line weight for line art is 0.5 point for optimal printing.

When possible, please place symbol legends below the Fig. instead of the side.

Original color Fig.s can be printed in color at the editor's and publisher's discretion provided the author agrees to pay.

Type or print out legends (maximum 40 words, excluding the credit line) for illustrations using double spacing, with Arabic numerals corresponding to the illustrations.

Sending a revised manuscript

While submitting a revised manuscript, contributors are requested to include, along with single copy of the final revised manuscript, a photocopy of the revised manuscript with the changes underlined in red and copy of the comments with the point-to-point clarification to each comment. The manuscript number should be written on each of these documents. If the manuscript is submitted online, the contributors' form and copyright transfer form has to be submitted in original with the signatures of all the contributors within two weeks of submission. Hard copies of images should be sent to the office of the journal. There is no need to send printed manuscript for articles submitted online.

Reprints

Journal provides no free printed, reprints, however a author copy is sent to the main author and additional copies are available on payment (ask to the journal office).

Copyrights

The whole of the literary matter in the journal is copyright and cannot be reproduced without the written permission.

Declaration

A declaration should be submitted stating that the manuscript represents valid work and that neither this manuscript nor one with substantially similar content under the present authorship has been published or is being considered for publication elsewhere and the authorship of this article will not be contested by any one whose name(s) is/are not listed here, and that the order of authorship as placed in the manuscript is final and accepted by the co-authors. Declarations should be signed by all the authors in the order in which they are mentioned in the original manuscript. Matters appearing in the Journal are covered by copyright but no objection will be made to their reproduction provided permission is obtained from the Editor prior to publication and due acknowledgment of the source is made.

Approval of Ethics Committee

We need the Ethics committee approval letter from an Institutional ethical committee (IEC) or an institutional review board (IRB) to publish your Research article or author should submit a statement that the study does not require ethics approval along with evidence. The evidence could either be consent from patients is available and there are no ethics issues in the paper or a letter from an IRB stating that the study in question does not require ethics approval.

Abbreviations

Standard abbreviations should be used and be spelt out when first used in the text. Abbreviations should not be used in the title or abstract.

Checklist

- Manuscript Title
- Covering letter: Signed by all contributors
- Previous publication/ presentations mentioned, Source of funding mentioned
- Conflicts of interest disclosed

Authors

- Middle name initials provided.
- Author for correspondence, with e-mail address provided.
- Number of contributors restricted as per the instructions.
- Identity not revealed in paper except title page (e.g. name of the institute in Methods, citing previous study as 'our study')

Presentation and Format

- Double spacing
- Margins 2.5 cm from all four sides
- Title page contains all the desired information. Running title provided (not more than 50 characters)
- Abstract page contains the full title of the manuscript
- Abstract provided: Structured abstract provided for an original article.
- Keywords provided (three or more)
- Introduction of 75-100 words

- Headings in title case (not ALL CAPITALS). References cited in square brackets
- References according to the journal's instructions

Language and grammar

- Uniformly American English
- Abbreviations spelt out in full for the first time. Numerals from 1 to 10 spelt out
- Numerals at the beginning of the sentence spelt out

Tables and Fig.s

- No repetition of data in tables and graphs and in text.
- Actual numbers from which graphs drawn, provided.
- Fig.s necessary and of good quality (color)
- Table and Fig. numbers in Arabic letters (not Roman).
- Labels pasted on back of the photographs (no names written)
- Fig. legends provided (not more than 40 words)
- Patients' privacy maintained, (if not permission taken)
- Credit note for borrowed Fig.s/tables provided
- Manuscript provided on a CDROM (with double spacing)

Submitting the Manuscript

- Is the journal editor's contact information current?
- Is the cover letter included with the manuscript? Does the letter:
 1. Include the author's postal address, e-mail address, telephone number, and fax number for future correspondence?
 2. State that the manuscript is original, not previously published, and not under concurrent consideration elsewhere?
 3. Inform the journal editor of the existence of any similar published manuscripts written by the author?
 4. Mention any supplemental material you are submitting for the online version of your article. Contributors' Form (to be modified as applicable and one signed copy attached with the manuscript)

Instructions to Authors

Submission to the journal must comply with the Guidelines for Authors. Non-compliant submission will be returned to the author for correction.

To access the online submission system and for the most up-to-date version of the Guide for Authors please visit:

<http://www.rfppl.co.in>

Technical problems or general questions on publishing with PER are supported by Red Flower Publication Pvt. Ltd.'s Author Support team (http://rfppl.co.in/article_submission_system.php?mid=5#)

Alternatively, please contact the Journal's Editorial Office for further assistance.

Editorial Manager

Red Flower Publication Pvt. Ltd.

48/41-42, DSIDC, Pocket-II

Mayur Vihar Phase-I

Delhi - 110 091(India).

Mobile: 9821671871, Phone: 91-11-79695648

E-mail: author@rfppl.co.in